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EFFECT OF METHYLTESTOSTERONE ON THE APOLIPOPROTEIN AND LIPID 
COMPOSITION AND ON THE APOLIPOPROTEIN METABOLISM 
OF CANINE SERUM LIPOPROTEINS
CHAPTER I 
REVIEW OF THE LITERATURE
Serum Lipoproteins 
Serum lipoproteins represent a heterogenous group of complex 
macromolecules consisting of several different lipid and protein compo­
nents. Their major function apparently is to transport the water-insol­
uble lipids, predominantly triglycerides, although they may also have 
other important transport and metabolic functions.
History
By the end of the 1920's it was generally recognized that lipids 
were present in the euglobulin fraction of serum proteins. The first 
lipoprotein preparation that contained reproducible proportions of lipids 
and proteins was obtained from horse serum by Macheboeuf in 1929 (1). 
Electrophoretic separation of proteins from normal human plasma indicated 
that the major portions of lipids were associated with a- and 3-globulin 
fractions (2). Fractionation of human plasma at low ionic strength in 
ethanol-water mixtures resulted in the precipitation of lipids into two 




Subjecting the serum to ultracentrifugation sedimented three pro­
tein components, i.e., albumin, globulin and X-protein (6). The X-protein 
complex was sensitive to changes in salt concentration and its flotation 
could be produced by increasing the density of the suspending medium (7). 
Flotation procedures were utilized for isolation and purification of this 
component which was characterized as ^“lipoprotein. The new method of 
quantitative analytical ultracentrifugation for studying these low density 
lipoproteins (LDL) was soon developed (8), and a possible role of LDL in 
the pathogenesis of atherosclerotic vascular disease postulated (9). The 
notation was then introduced for classification and characterization 
of serum lipoproteins according to their flotation rates in a sodium chlo­
ride solution of d 1.063 g/ml at 26° C (10, 11). Ultracentrifugation at 
a higher solvent density, i.e., d 1.210 g/ml permitted flotation of the 
high density lipoproteins (HDL). The HDL and LDL fractions isolated by 
ultracentrifugation corresponded with the a- and 3-fractions, respective­
ly, separated by electrophoresis (12). Immunochemical studies suggested 
that these two major lipoprotein classes were antigenically distinct and 
that these characteristics represented properties of the protein rather 
than tire lipid moieties of the lipoproteins (13, 14).
N-terminal amino acid analyses indicated that HDL and LDL con­
tain distinct protein moieties (15-17), inasmuch as N-terminal aspartic 
acid was found in HDL and glutamic acid in LDL. Additional N-terminal 
amino acids have also been found, predominantly in the very low density 
lipoproteins (VLDL, < 1.006 g/ml) and lymph chylomicrons (16-20). This 
observation suggested that apolipoproteins in addition to apolipoproteins
3
A and B, which represent the principal apolipoproteins of HDL and LDL, 
respectively, may be present in plasma. Investigation of this possibil­
ity led to the conclusion that a third apolipoprotein, designated apo­
lipoprotein C, may represent a major VLDL apolipoprotein in human plasma 
(21, 22) .
These major developments represent the framework for the present 
knowledge of serum lipoproteins. Much of this knowledge, particularly the 
more detailed structural and compositional aspects, is based on informa­
tion concerning human plasma lipoproteins. This emphasis relates to the 
significance of lipoproteins in atherogenesis.
Classification and Nomenclature
The principal classification systems are based on hydrated den­
sities and paper electrophoretic characteristics of lipoproteins. It has 
become increasingly evident during the last decade that the lipoprotein 
classes separated by either of these methods contain more than one pro­
tein component (Table 1). An alternative system has been proposed in 
which lipoproteins are classified by their apolipoprotein component into 
groups designated as lipoprotein A, lipoprotein B and lipoprotein C (23). 
However, significant new information obtained during the last two years 
indicates a much greater complexity in respect to the protein components 
than was previously recognized.
According to the density classification system, the lipoprotein 
spectrum consists of the five classes shown in Table 1. The concentra­
tion and composition of these lipoprotein fractions in human serum are 
presented in Table 2. The distribution of serum lipoproteins in males 
differs from that in females, inasmuch as males have higher concentrations
TABLE 1
CLASSIFICATION AND NOMENCLATURE OF HUMAN SERUM LIPOPROTEINS*
Hydrated Density













Chylomicrons > 0.950 > 400 origin Ser,Thr Glu,Asp C,B,A
VLDL 0 .950-1.006 20-400 pre-B Ser,Thr Glu,Asp C,B,A
LDL 1 .006-1.063 0-20 3 Glu Ser,Thr,Asp B,(C),(A)
HDL 1,.063-1.210 — a Asp Glu,Ser,Thr A,(B),(C)
VHDL > 1.210 — a Asp - A
^Abbreviations : VLDL = very low density lipoproteins; LDL = low density lipoproteins; HDL =
high density lipoproteins; VHDL = very high density lipoproteins.
^Negative sedimentation coefficient in Svedberg units in NaCl solution of d 1,063 g/ml at
26° C.
TABLE 2






Class Male Female Protein Cholesterol 
Free Ester
Phospholipid Triglyceride
Chylomicrons 12+ 13 2± 3 2 2.1 3.9 4.3 87
VLDL 129+122 59± 63 5-12 3-5 10-13 13-20 50-60
LDL 439+ 99 389± 79 22 10 36 20 12
HDL 300± 83 4571115 50 2 20 24 4
VHDLC - - 62.4 0.3 3.2 28 4.6
^Values obtained from ref. 120 are expressed as mean ± standard deviation.
^Values were obtained from ref. 46.
^Values were obtained from ref. 121 for the fraction of d 1.210-1.250 g/ml.
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of VLDL and LDL and lower concentrations of HDL than females. Further­
more, LDL and/or VLDL levels increase with age from the third to the 
fifth decade, while no significant age trends are observed for HDL in 
either sex (24).
Structural Properties
Essentially all of the lipid can be extracted from lipoproteins 
with appropriate organic solvents to produce a lipid-free glycoprotein
(25). This observation supports the conclusion that the major forces 
holding the lipid and protein components of the lipoprotein together are 
non-covalent. It has been suggested, however, that a small amount of 
fatty acid may be covalently bound to the protein (26). The lipoprotein 
classes are considered to be polydisperse systems which are heterogeneous 
in respect to particle size, hydrated density (27, 28) and protein moiety 
(23). Two basic types of lipoproteins have been postulated on the basis 
of structural features (29). One of these, the micellar type, contains 
less than 30% protein and includes chylomicrons, VLDL and LDL, while the 
other contain more than 30% protein and includes HDL and VHDL.
Micellar lipoproteins are thought to consist of a hydrophobic 
core of triglycerides and cholesterol esters, surrounded by a hydrophilic 
coat of protein, phospholipid and free cholesterol. Chylomicrons, VLDL 
and LDL appear by electron microscopy as spherical particles with diame­
ters of approximately 1,200 to 11,000 A, 300 to 700 A and 170 to 260 A, 
respectively (30, 31). No specific sub-unit structure is evident. Be­
yond these similarities, however, there are important differences among 
these lipoproteins concerning the type and amount of apolipoproteins and 
lipids. For example, in chylomicrons and VLDL an increasing number of
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protein or polypeptide components are being identified (32-34). The LDL 
are also heterogeneous in respect to their protein moiety (35) although 
proportions of apolipoproteins in LDL differ from those in chylomicrons 
and VLDL.
The HDL and VHDL are thought to consist of sub-units containing 
protein and lipid. These sub-units associate in a definite quaternary 
structure with a mean diameter of 74 to 98 A, which is recognizable by 
the electron microscope (30). HDL is frequently sub-divided into HDL2 
(d 1.063-1.125 g/ml) and HDL3 (d 1.125-1.210 g/ml) which are heterogeneous 
in respect to their protein moiety. Apolipoprotein A contains at least 
two non-identical polypeptides characterized by their C-terminal amino 
acids (R-Gln and R-Thr) in either HDL2 or HDL3 (36, 37). Some of the 
polypeptides found in HDL2, in addition to apolipoprotein A, are possibly 
due to the presence of apolipoproteins B and C (38, 39). Optical measure­
ments suggest that HDL is relatively rich in the a-helical conformation. 
This contrasts with native LDL, which contains a significant amount of 
anti-parallel chain S-structure (40-42). Measurements of circular dichro- 
ism and total amino acid content of the two major polypeptide sub-units of 
HDL indicate that R-Thr has a greater helical content than R-Gln (43). 
Since helical regions are generally on the surface of proteins rather than 
in the hydrophobic interior of the molecule, it is suggested that the R- 
Thr polypeptide might be involved to a lesser extent in lipid binding than 
the R-Gln polypeptide.
Despite significant progress during the last few years, present 
knowledge concerning the chemistry of the apolipoproteins is still insuf­
ficient for answering questions about the nature of lipid-protein inter-
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actions and about those specific structural features which are necessary 
for lipid binding. Since the amino acid composition of the protein moi­
eties of different lipoprotein classes does not differ significantly from 
that of other serum proteins, the elucidation of specific amino acid se­
quences of the individual peptides will probably be required to permit a 
better understanding of the relationship between lipoprotein structure 
and function.
Functions and Interrelationships
Triglycerides are a major source of fatty acids and thereby func­
tion in the physiological role of a principal energy reserve. Chylomi­
crons and VLDL, which are triglyceride-rich lipoproteins, appear to be 
primarily involved in energy metabolism. Although the role of cholesterol 
esters has not been defined, it is well established that free cholesterol 
serves as the precursor of bile acids and steroid hormones. LDL and HDL 
are primarily responsible for sterol transport. The main function of 
phospholipids is stabilization of the lipoprotein structure and of the 
highly apolar lipids during their transport in aqueous media. Phospho­
lipids are concentrated at polar-apolar interfaces along with the apo­
lipoproteins. Binding of phospholipid may be the major function of apo­
lipoproteins which have a high affinity for phospholipid (21, 22, 44, 45).
Several lines of evidences indicate that the presence of high 
concentrations of triglyceride-rich VLDL affect the concentration and 
composition of LDL and HDL. A direct relationship has been observed be­
tween plasma levels of VLDL and the percentage content of triglyceride 
in HDL (46). Similarly, in vitro incubation of plasma with high levels 
of VLDL resulted in a significant increase in the triglyceride content
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of HDL and LDL fractions (47) , while a reciprocal transfer of cholesterol 
esters of LDL and HDL occurred. Additional evidence that triglyceride 
metabolism influences the concentration of lipoproteins which contain 
little triglyceride is provided by the observation that VLDL and LDL lev­
els show an inverse relationship with HDL2 (24). ^  vivo and i^ vitro
studies have demonstrated that lecithin, free cholesterol and triglycer­
ide (48, 49), but not cholesterol esters (50), undergo continual exchange 
among lipoprotein fractions.
The fact that lipoprotein classes share common protein or poly­
peptide components may represent the fundamental chemical basis for their 
interrelationships. Chylomicrons and VLDL probably contain the full com­
plement of their apolipoprotein components upon release from the intestine
and/or liver (51). In addition, they may pick up apolipoprotein A during
1 ncirculation since both in vivo and in vitro studies show that HDL- I 
bind to chylomicrons (52). It is possible that the function of bound 
apolipoprotein A is to activate lipoprotein lipase (45, 53) and/or leci­
thin: cholesterol acyl transferase (LCAT) (54) and thereby play a role in 
the metabolism of these lipoproteins. After in vivo heparin administra­
tion, chylomicrons and VLDL are rapidly degraded into smaller lipoprotein 
products which have ultracentrifugal flotation properties similar to LDL 
and HDL (55). While the chemical properties of the LDL products are sim­
ilar to those of normally occurring LDL, the HDL products contain an ap­
preciable amount of phospholipid and less of other lipid components which 
normally occur in HDL (56). The lipid composition of the HDL product may 
be normalized by a sequence in which cholesterol ester is formed by an 
LCAT-catalyzed reaction between lecithin and free cholesterol. The cho­
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lesterol ester formed in HDL from lecithin and free cholesterol, which 
was transferred from chylomicrons or VLDL to HDL during lipolysis, is 
subsequently transferred back into the VLDL. The possibility that this 
LCAT-catalyzed reaction involving HDL is a significant pathway for cho­
lesterol ester formation is supported by the fact that LCAT inhibitors 
markedly reduce this transfer ^  vitro, and that newly synthesized cho­
lesterol ester appears most rapidly in HDL (57, 58). A precursor-product 
relationship between the VLDL and LDL is suggested by tracer studies in 
vivo using protein-labeled lipoproteins (52, 59), and by investigations 
evaluating changes in lipoprotein distributions during metabolic (60) and 
pharmacologic (61, 62) alterations in which substantial shifts in plasma 
lipoprotein distributions were characterized by marked decreases in VLDL 
and increases in LDL and HDL levels.
The function of apolipoprotein B appears to be its essential role 
in the formation and secretion of chylomicrons and VLDL by the intestine 
and liver. Evidence favoring this conclusion is provided by studies of 
abetalipoproteinemia, a human genetic disorder (63), as well as by re­
sponse to agents such as puromycin (64) or orotic acid (65) which inhibit 
synthesis of this protein.
Serum lipoproteins may play an important role in maintaining red 
blood cell membranes and probably other tissue membranes in a functional 
state. It has long been known that the free cholesterol of plasma is in 
rapid equilibrium with the free cholesterol of the erythrocytes (48, 66, 
67). In addition, it has been reported that phospholipid exchange also 
occurs between erythrocytes and lipoproteins (68, 69). Lecithin and 
sphingomyelin in HDL and LDL and lysolecithin in VHDL are involved in
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this process. It is possible that new lecithin molecules for the red 
cells are derived through an exchange of red cell lecithin for lysoleci­
thin from serum (70). The red cell abnormalities in a number of diseases 
(abetalipoproteinemia, a-lipoprotein deficiency and LCAT deficiency) most 
likely reflect an imbalance in the serum lipoprotein system. Furthermore, 
patients with abetalipoproteinemia frequently show neurological defects 
associated with partial demyelination, and in some cases of a-lipoprotein 
deficiency peripheral neuropathies have been observed. These observations 
may reflect the dependence of tissue membranes on plasma lipoproteins.
This proposed interrelationship is consistent with the fact that different 
cellular and subcellular membranes have been found to exchange cholesterol 
with serum lipoproteins (71).
The transport of carotenoids by serum lipoproteins (72-74) repre­
sents another important biological function (75).
Synthesis and Catabolism of Apolipoproteins
Many of the details of protein synthesis, as well as pathways for 
synthesis and breakdown of different lipid components, are now well-known. 
However, little information is available to provide a reasonably clear 
concept of the formation and degradation of lipoproteins as a macromolecu- 
lar entity. The limited knowledge in this field may be due to several 
possible reasons, including the incomplete characterization of the chem­
istry and number of apolipoprotein polypeptides and the large number and 
poorly defined interrelations and interconversions of lipoprotein compo­
nents. The possible models suggested for lipoprotein biosynthesis (76) 
are built around the concept that the protein moiety plays a cardinal 
role in this process. This thesis is consistent with structural consid­
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erations discussed above, as well as the observation that the interaction 
of highly specific protein with reconstituted lipid-bilayer membranes pro­
duces profound alterations in the electrical characteristics of the lipid- 
bilayer (77). The observation that individual lipoprotein components have 
distinct turnover rates (78) favors the conclusion that serum lipoprotein 
metabolism resembles that of cellular membranes (79). Furthermore, the 
turnover of triglyceride, cholesterol ester and other components of indi­
vidual lipoprotein fractions depends on the lipoprotein class in which the 
component is transported (58). Additional studies will be required to 
determine whether this reflects the influence of apolipoprotein or parti­
cle size of individual lipoproteins.
It has been generally accepted that all plasma proteins except 
gamma-globulins are synthesized in the liver (80). The intestine may 
serve as an extra-hepatic site for apolipoprotein synthesis, however, in­
sofar as chylomicron formation is considered. Results from vivo stud­
ies in dogs fed labeled amino acids have suggested an intestinal origin 
for at least a part of the chylomicron protein (81). ^^C-leucine was in­
corporated into chylomicrons by rat intestinal mucosa (82, 83). Further­
more, little radioactivity was incorporated into VLDL in hepatectomized 
dogs and none was observed following evisceration (84). These studies 
also indicate that in the synthesis of lipoprotein classes other than 
chylomicrons the intestine does not play any significant role.
Experiments with rat liver slices and with perfused livers dem­
onstrated the net synthesis of LDL apolipoprotein, which was shown by a 
quantitative precipitin method to be identical with that circulating in 
the blood (85), and of HDL apolipoprotein, which was similar by peptide
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finger printing and labeling technique to that found in plasma HDL (86).
Amino acid incorporation studies of the synthesis of LDL and 
HDL apolipoproteins, in various laboratory animals and experimental con­
ditions (87-89), have repeatedly demonstrated that LDL apolipoprotein 
has a higher specific radioactivity, and presumably a greater turnover 
rate, than HDL apolipoprotein. In studies with perfused rat livers in 
which mevalonic acid served as precursor (50), LDL cholesterol esters 
had a more rapid turnover than those in HDL. Studies in rabbits of the 
disappearance of LDL and HDL containing ^^C-labeled protein indicated no 
significant metabolic interconversion between them (87). Similarly, stud­
ies in man with ^^^I-labeled lipoproteins have demonstrated that LDL apo­
lipoprotein had a shorter half time than that of HDL, and that labeled 
LDL peptides were not found subsequently in HDL (90).
It has been shown that the intracellular site of apolipoprotein 
synthesis is in the microsomal fraction (91) and that isolated rat liver 
ribosomes, in an essentially lipid-free system, but not mitochondria or 
kidney microsomes can synthesize the LDL and HDL apolipoproteins (92).
The labeled peptides can be removed from the ribosomes and combined with 
lipid to form lipoprotein. The tentative conclusion from these experi­
ments is that the presence of all lipid classes in lipoproteins is not 
required for the synthesis of the protein moiety, although their role in 
the release of polypeptides from the ribosomes is not clear. Similarly, 
information is lacking concerning the attachment of the small amount of 
covalently-bound carbohydrate found in apolipoproteins and the role it 
may play in the lipid binding, i.e., in the overall configuration of the 
apolipoprotein and the assembly of the lipoprotein, or possibly in the
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transport from the cell (93) in which the apolipoprotein is formed. The 
presence of a small amount of covalently-bound fatty acids in lipoproteins
(26) adds another facet to the problem.
Electron microscopic studies in perfused rat liver showed that 
soon after raising the free fatty acid concentration in the perfusate, 
strongly osmophilic bodies of 300-800 A, probably representing VLDL, ap­
peared in the smooth endoplasmic reticulum and Golgi apparatus and later 
in the space of Disse (94, 95). These observations suggested that the 
Golgi apparatus participated in the formation and secretion of VLDL. Re­
cently, in similar studies the Golgi apparatus has been isolated and the 
presence of all apolipoprotein components of circulating VLDL has been 
demonstrated by chemical analyses (51).
Although several factors are known to influence the synthesis of 
apolipoproteins, the regulation of serum lipoprotein synthesis is far from 
being understood. Most of the agents, or conditions, known to produce 
fatty liver interfere with apolipoprotein synthesis. Ethionine (96) or 
puromycin (97) administration decreased the ability of liver slices to 
incorporate leucine into LDL and HDL. Carbon tetrachloride poisoning re­
sulted in a marked decrease of leucine (98) or lysine (89) incorporation 
into lipoproteins. In perfused livers from orotic acid-fed rats, LDL 
production was inhibited without altering the release of HDL, albumin and 
other proteins (99). Actinomycin treatment caused rapid depression of 
VLDL and LDL levels in the rat while HDL and other serum proteins were 
less affected. The incorporation of lysine into LDL was decreased most, 
although a reduced incorporation into HDL and albumin was also observed 
(100). On the other hand, triglyceride feeding (101) or an increased
15
free fatty acid influx into the perfused liver (102) resulted in a greater 
production of triglyceride-rich VLDL with an increased incorporation of 
amino acids into VLDL but not HDL apolipoproteins. Puromycin markedly 
depressed the production of VLDL by livers perfused with fatty acid-rich 
medium by inhibiting protein, but not triglyceride, synthesis (94).
These studies indicate that the liver is the major source of all 
apolipoproteins and that their unimpaired synthesis is essential for nor­
mal lipid transport and metabolism. On the other hand, the mechanisms 
and sites of apolipoprotein degradation are entirely unknown. Although 
lipoproteins may be completely assembled as a result of de novo synthesis 
in the liver prior to leaving the cell, the different turnover rates of 
their components clearly indicate that they are not degraded as a whole. 
The fact that apolipoproteins have longer half times than the lipid com­
ponents except cholesterol may be related to the exchanges of lipids be­
tween circulating lipoproteins and cell membranes, and might also accomo­
date yet unproven concepts of recycling apolipoproteins (53, 103).
Species Differences
The transport functions of plasma lipoproteins in other mammalian 
species are presumed to be similar to those in man. However, it has long 
been recognized that the distribution among the lipoprotein spectrum was 
different in most animals when compared with man (12, 104, 105). The pig 
and monkey were found to have a lipoprotein distribution pattern similar 
to that of man, while a dissimilar distribution was observed in the rat, 
rabbit, chicken, dog, cat, guinea pig and hamster. The guinea pig has al­
most no HDL, while other animals differ from humans mainly in that the HDL 
fraction contains a significant proportion of their lipid. More recently.
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the bison (106), cow (107), marine mammals (108) and some migratory birds 
(74) were also found to differ from the pattern in human subjects. Fur­
thermore, some of these studies indicated that species differences also 
exist in respect to the lipid composition of the lipoprotein classes. 
Paper electrophoretic (109) and zonal ultracentrifugal (110) studies of 
lipoprotein distributions of several animal species confirm the previous 
findings.
Remarkable similarities were found in the immunological charac­
teristics of LDL from human and animal sera. LDL from chicken serum are 
the only LDL in the many species examined which have failed to show any 
cross-reaction with human LDL (111-113). Comparable information is not 
available, however, regarding the immunological characteristics of HDL 
in different animal species. In general, few reports have appeared con­
cerning the distribution and chemical characteristics of specific apoli- 
poproteins. Detailed analyses of lipoproteins and apolipoproteins have 
been reported for the pig (114-116) and the rat (51, 117-119). On the 
basis of these studies, it appears that an apolipoprotein pattern which 
is similar in complexity to that found in human lipoproteins can be ex­
pected in other animal species. Beyond these superficial similarities 
in chemistry and structure, however, specific characteristics in compo­
nents and/or composition of apolipoproteins should be found to explain 
the species differences in lipoprotein distribution and composition, as 
well as in some aspects of lipid transport and metabolism (74).
Methyltestosterone
Soon after the chemical structure of the male sex hormone, tes­
tosterone, was elucidated and the chemical synthesis achieved in 1935,
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a number of analogs and derivatives were prepared. Methyltestosterone 
(17a-methyl-173-hydroxyandrosta-4-en-3-one, Figure 1) is unique among 17a- 
substituted alkyl derivatives in retaining androgenic potency when given 
orally.
Although testosterone is effective when given parenterally, it 
is practically inactive by oral administration (122, 123). This is due 
to the rapid inactivation of testosterone in the liver (124). Earlier 
investigations have shown that 17-ketosteroid excretion is markedly in­
creased by testosterone, but is either unaltered or lowered by methyltes­
tosterone (125-127). This observation was supported by vitro experi­
ments with liver showing that no 17-ketosteroid was formed from methyl­
testosterone (128), and by the finding that 17a-alkylation lowers the ease 
with which 173-hydroxyl groups may be oxidized (127, 129). Thus, substi­
tution of an alkyl group in the 17a-position prevents the oxidation of the 
173-hydroxy group of testosterone (by the 173-hydroxysteroid dehydrogen­
ase) , thereby impeding and directing to other pathways the metabolism of 
methyltestosterone. Methyltestosterone was introduced into clinical medi­
cine in 1939 (123) and has become the prototype of orally active androgens 
and synthetic anabolic steroids.
Biological Effects of Androgens
Androgens promote general body growth (hence their designation 
as anabolic steroids) and also produce masculinizing effects. Anabolism 
means a preponderance of protein synthesis, a constructive metabolism 
which is recognized by a positive nitrogen balance. The androgenic effect 
differs from the anabolic effect primarily in its location. Androgenicity 
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Flg. 1 - Chemical formula of testosterone and 17a-methyltestosterone.
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tion, while in the common usage of the term an anabolic effect signifies 
the extragenital stimulation of protein synthesis.
Testosterone is one of the most potent anabolic steroids known. 
Studies on the incorporation of amino acids into tissue protein indicated 
that testosterone does not slow down protein breakdown but rather stimu­
lates protein synthesis (130-132). Similarly, investigation of the dy­
namics of protein metabolism in man showed that anabolic steroids did not 
inhibit protein degradation, but stimulated protein synthesis exclusively 
(133). At the molecular level two fundamental activities have been dem­
onstrated as influenced by anabolic steroids, i.e., an increase of the 
ribonucleic acid (RNA) content of cells and an increase in the activities 
of amino acid activating enzymes (134-136). Testosterone is bound to a 
protein component of the chromatin at the site of active RNA synthesis 
within the nuclei of accessory sex tissues (137). This occurs after con­
version of testosterone by nuclear 5a-reductase into the more potent an­
drogen, dihydrotestosterone, which appears to be the active form of tes­
tosterone in these tissues (138). However, in the same study dihydrotes­
tosterone formation in non-target tissues, e.g. liver and muscle, was 
negligible. Polar metabolites other than dihydrotestosterone were formed 
when testosterone was incubated with liver nuclei or liver cytoplasm.
These results indicate that the metabolic actions of androgens are medi­
ated possibly through different metabolites in different tissues. This 
is in agreement with the fact that chemical modifications of testoster­
one resulted in significant dissociations of the anabolic and androgenic 
effects.
Investigations into the effect of androgens on the concentrations
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of total protein and protein fractions in serum have yielded inconclusive 
results. The influence of anabolic steroids on serum protein fractions 
has not been evaluated adequately in healthy subjects and laboratory ani­
mals. No characteristic change in serum total protein concentration has 
been observed during testosterone treatment of patients with a variety of 
diseases (139). Administration of either natural androgens or synthetic 
anabolic steroids, however, produced an increase in the ag-globulin frac­
tion (140, 141). Methyltestosterone administration to human subjects de­
creased the thyroxine-binding capacity of the thyroxine-binding globulin, 
suggesting that the concentration of this protein in serum was lower (142), 
Norethandrolone produced a similar response in thryoxine-binding globulin, 
but increased the thyroxine-binding capacity and the concentration of the 
thyroxine-binding pre-albumin fraction (143).
Effects on Lipid Metabolism 
Sex differences in the development of atherosclerosis as well as 
the resistance of male castrates to coronary heart disease have long been 
recognized. Although sex differences exist in respect to serum lipid and 
lipoprotein concentrations, and administration of gonadal hormones char­
acteristically alters the lipid levels and lipoprotein patterns in the 
serum (144), it is not at all clear what is the significance for athero- 
genesis of these effects of gonadal hormones (145). In general, the ad­
ministration of androgens to subjects with normal serum lipid levels di­
minishes the concentration of HDL and to a lesser extent increases the 
concentration of LDL, which are changes opposite to those elicited by 
estrogens (146-148). Although serum cholesterol .evels may not change 
significantly in healthy subjects, in lipemic patients the hypocholes-
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terolemic effect of methyltestosterone and other androgens has been well 
documented (149-152). In the dog, testosterone or methyltestosterone ad­
ministration lowers the concentration of both HDL and LDL (153) and re­
duces serum cholesterol, phospholipid and triglyceride levels (153-155).
These data clearly indicate that methyltestosterone and testos­
terone exert a similar effect on serum lipoproteins. The mechanism whereby 
these effects are produced has not been determined. The observation that 
methyltestosterone decreased the incorporation of acetate into serum cho­
lesterol (156) may provide an explanation for the changes in cholesterol 
metabolism, but this explanation is inadequate to account for the marked 
decrease which was demonstrated in all three major lipid classes. A 
major fecal metabolite of methyltestosterone, i.e., 17a-methyl-5a-andro- 
stane-33,173-diol, has been found recently to reproduce completely the 
hypocholesterolemic effect of methyltestosterone (157) in dogs. These 
results suggest that there is no direct relationship between the andro­
genicity and the hypocholesterolemic activity, inasmuch as the metabolite 
appeared to be a much weaker androgen than the parent compound (158). The 
possibility that the metabolite isolated from the feces of methyltestos- 
terone-treated dogs (159) may be the active compound still leaves unan­
swered the question concerning the mechanism of action of methyltestos­
terone.
Methyltestosterone has also been found to lower serum cholesterol 
concentrations in rabbits (160), although this agent had no effect in pre­
venting hypercholesterolemia, tissue lipid deposits or aortic and coronary 
atherosclerosis in cholesterol-fed rabbits, nor did it modify previously 
developed lesions (161). Reports describing a hypocholesterolemic effect
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in rats (162) were not confirmed by others (163). In the latter study, 
methyltestosterone produced a significant decrease in hepatic cholesterol 
synthesis, but this response was compensated by a significant increase in 
intestinal cholesterol synthesis and total cholesterol biosynthesis in 
these tissues remained unaltered. The oxidation of cholesterol to biliary 
and fecal bile acids was not increased significantly in rats treated with 
methyltestosterone (164).
Prolonged administration of high doses of testosterone or 17a- 
methylandrost-5-ene-36,17B-diol has been reported to decrease the total 
fat content of the body (165-167). On the other hand, testosterone treat­
ment of starved female rats caused a marked increase in plasma free fatty 
acid concentrations, suggesting the possibility of a direct fat-mobilizing 
activity of the androgens (168). These observations and others, i.e., 
that during puberty the subcutaneous fat decreases in males but not in fe­
males and that eunuchs have a tendency to obesity, seem to warrant inves­
tigations on the role androgens may play in adipose tissue metabolism.
At the present, however, such information is not available.
Side-effects and Metabolism of Methyltestosterone
Although the biological effects of methyltestosterone are gener­
ally equivalent to those of testosterone, even insofar as producing an 
apparent feed-back regulation of gonadotropin secretion and testosterone 
production (169), the effects of methyltestosterone on creatine metabolism 
and on the conjugative or excretory functions of the liver differ from 
those of the natural hormone. Testosterone lowers the hypercreatinuria 
caused by castration (170), or by thyroxine administration (171), and re­
duces the excretion of creatine and creatinine in normal persons as well
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(172). On the other hand, methyltestosterone produces a pronounced in­
crease in urinary excretion and serum levels of creatine (171, 173) and 
guanidinoacetate (173, 174), its physiologic precursor. In the absence 
of any change in kidney threshold, it is possible that the hypercreatin­
uria is due to increased creatine synthesis. Arginine and methionine are 
required in the formation of guanidinoacetate and its subsequent méthy­
lation to form creatine. The possibility therefore exists that methyltes­
tosterone may increase the utilization of these two amino acids for crea­
tine synthesis. For this reason, it appears unwise to consider the use 
of either of these two essential amino acids or glycine as precursors in 
studying the effect of methyltestosterone on protein synthesis.
The original observation (175) suggesting that methyltestosterone 
might cause obstructive jaundice led to the recognition that prolonged ad­
ministration of 17a-alkyl substituted steroids can cause hepatic dysfunc­
tion due to intrahepatic cholestasis (176). In addition to development 
of icterus, these agents may produce acholic feces, an increase in serum 
bilirubin concentration, impaired removal of bromsulphalein and an in­
crease in the serum activities of alkaline phosphatase and glutamic-oxal- 
acetic transaminase. No direct relationship has been found between the 
duration or dosage of methyltestosterone treatment and the appearance of 
these side-effects. On the other hand, the prognosis is generally good,
i.e., complete recovery usually occurs after methyltestosterone adminis­
tration is suspended. The hepatocytes exhibit only minor histological 
changes and remain viable (177, 178). Electron microscopic observations 
led to the conclusion that the primary damage occurs in the canalicular 
membranes of liver cells (179). Alternatively, continuous administration
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of methyltestosterone for years may lead to biliary cirrhosis (180).
It is likely that these special side-effects of methyltestoster­
one are due to its being metabolized in a different way than testosterone. 
Howe'' r, while the intermediary metabolism of natural androgens has been 
elucidated in practically all details (181), information regarding the 
metabolism of methyltestosterone is incomplete. The intermediary metabo­
lism of testosterone proceeds essentially via three main reactions:
1. 173-hydroxysteroid dehydrogenase: oxidation of the 173-
hydroxy group resulting in 17-ketosteroid formation (androstenedione),
2. A^-5a- or A^-53-reductase: reduction of the 4,5-double
bond in ring A, and
3. 3a- and 33-hydroxysteroid dehydrogenase: formation of the
3-hydroxy-5-androstan-17-one metabolites (4 isomers).
It has long been known, as mentioned above, that methyltestos­
terone does not undergo the first reaction. However, from the available 
information on some of the metabolites of methyltestosterone it would 
appear that its metabolism by the other two reactions is not impaired. 
After the administration of labeled methyltestosterone to human subjects, 
17a-methyl-5a-androstane-3a,173-diol and its 53:3a isomer were isolated 
in the feces and urine, in addition to unchanged methyltestosterone and 
unidentified polar compounds (182, 183). Methyltestosterone disappeared 
from the plasma with a half time of about 2.5 hr, while plasma con­
jugated steroids containing radioactivity administered as methyltestos­
terone began to increase soon after the injection and reached a plateau 
within 2 to 6 hr. Furthermore, about three-quarters of the urine radio­
activity was found in the conjugated steroid fraction, in which the por­
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tion esterified with glucuronic acid exceeded that with sulphuric acid.
The excretion of radioactivity in urine and feces also appeared to be 
slow, inasmuch as only 50% of the injected dose had been excreted after 
4 days (183). These results indicate that methyltestosterone is metabo­
lized significantly more slowly than testosterone, which disappears from 
plasma with a half time of about 30 min (184). In addition, methyltestos­
terone and its metabolites are conjugated to a lesser extent, although 
qualitatively these metabolites resemble those of testosterone (185).
Renal clearance of methyltestosterone and its metabolites may also be 
lower. The fact that clearly the greater portion of the metabolites were 
hydroxylated and reduced in ring A differentiates the metablism of methyl­
testosterone from that of most other steroid hormones.
In the dog, the metabolic fate of methyltestosterone appears to 
be similar in many respects to that in man (159). The same metabolites 
could be identified in the feces and urine in both species. However, in 
the dog more than 95% of the dose of radioactivity administered daily was 
recovered in urine and feces. No appreciable amount of labeled material 
could be detected in the tissues as early as 24 hr after the last in­
jection. This indicates that methyltestosterone is metabolized and ex­
creted at a more rapid rate in the dog than in man. The metabolic clear­




The present study was undertaken to evaluate the mechanism where­
by androgens lower the concentrations of serum lipids and lipoproteins. 
Interest in this research problem was prompted in part by the signifi­
cance of gonadal hormones in relation to atherosclerosis and heart dis­
ease. Furthermore, results obtained in this study should provide addi­
tional knowledge concerning the role of gonadal hormones in the regula­
tion of lipid transport and metabolism.
The dog was selected as the laboratory animal for these studies 
in order that each animal might serve as his own control and studies could 
be performed in which a series of blood samples are obtained from each 
animal. While many studies of lipid transport and metabolism in which a 
relatively large laboratory animal is desirable have been performed in 
the dog, limited information is available concerning the characteristics 
of canine serum lipoproteins, particularly the distribution of apolipo­
proteins among the lipoproteins. In the present study, a series of ca­
nine serum lipoprotein fractions was isolated by sequential preparative 
ultracentrifugation. The apolipoprotein and lipid composition of the 
purified lipoprotein fractions was then characterized by immunochemical 
and quantitative chemical analyses.
Previous studies have shown that the administration of methyl-
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testosterone significantly lowers the concentration of cholesterol, phos­
pholipid and triglyceride in serum HDL and LDL. All serum lipids are de­
creased to approximately the same degree. In view of the major role of 
apolipoproteins in the formation and structure of lipoproteins, the possi­
bility exists that methyltestosterone exerts its effect on lipoproteins 
through a primary effect on apolipoprotein metabolism.
Studies were undertaken to characterize the changes elicited by 
methyltestosterone in apolipoproteins of serum lipoproteins. The apolipo- 
tein and lipid distribution in serum lipoproteins, as well as the composi­
tion of purified lipoprotein fractions were determined in serum samples 
obtained before and during methyltestosterone administration. Quantita­
tive data were also obtained for serum albumin and conventional globulin 
fractions. Metabolic studies were performed in which the effect of methyl­
testosterone on the incorporation of ^^C-lysine into the apolipoproteins 
of serum HDL and LDL and into serum albumin was evaluated. In addition, 
measurements were obtained of the turnover of HDL apolipoprotein follow­
ing the administration of purified HDL containing ^^C-labeled apolipopro­
tein and of albumin turnover following l^C-albumin administration, in 
studies performed before and during methyltestosterone treatment. Turn­





Mature mongrel dogs were maintained on a commercial dog food with 
an approximate caloric composition of 28% protein, 18% fat and 54% carbo­
hydrate (Superior Tast-Tee Chunks Dog Food, Superior Feeds, Oklahoma City, 
Okla.). Body weight was monitored weekly and diet ration was adjusted to 
maintain body weight constant.
A group of ten dogs (9 males, 1 female) was used in studies of 
the apolipoprotein and lipid distribution in serum lipoproteins and the 
composition of purified lipoprotein fractions. After a 20-hr fast, the 
dogs were anesthetized with sodium pentobarbital (30 mg per kg, i.v.) and 
150 to 200 ml of blood was obtained through a femoral vessel.
Another group of four dogs (3 males, 1 female) was used in the 
methyltestosterone studies, in which apolipoprotein and lipid distribution 
in serum lipoproteins and the composition of purified lipoprotein frac­
tions were analyzed and incorporation and turnover studies were performed 
before and during methyltestosterone administration. Blood samples were 
obtained at weekly intervals from each dog for analyses of serum choles­
terol, phospholipid, triglyceride, total protein and individual protein 
fractions. An additional 200 ml of blood for lipoprotein analysis was
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obtained from each dog after a 20-hr fast. Liver function was evaluated 
by measurements of serum bilirubin concentration and bromsulphalein reten­
tion. Methyltestosterone, 200 mg per day 5 days per week, was then admin­
istered to each dog and studies similar to those during the control period 
were performed after serum lipid levels had stabilized at a new low level 
characteristically produced by methyltestosterone. Incorporation and 
turnover studies were performed no earlier than 7 weeks after initiation 
of methyltestosterone administration, to insure that a metabolic steady 
state had been attained. Immediately before and during these metabolic 
studies, 200 mg of methyltestosterone was administered daily.
Preparative and Analytical Procedures
Isolation and Purification of Lipoprotein Fractions 
Sequential preparative ultracentrifugation was used to isolate 
lipoprotein fractions in the following density ranges: d < 1.006 g/ml,
very low density (VLDL); d 1.006-1.019 g/ml and 1.019-1.063 g/ml, low 
density (LDL); d 1.063-1.110, 1.110-1.160, 1.110-1.210 and 1.160-1.210 
g/ml, high density (HDL); and d 1.210-1.250 g/ml, very high density 
(VHDL) (Figure 2, scheme A). Seven ml of serum in a polyallomer tube was 
overlayered with 4 ml of sodium bromide solution, d 1.006 g/ml, and cen­
trifuged at 4° C in a type 50 rotor for 22 hr at 105,000 x g in a Spinco 
Model L or L-2 preparative ultracentrifuge (Beckman Instruments, Inc.,
Palo Alto, Calif.). After removing the top 2 ml from the tube with the 
aid of a tube slicer, the infranatant portion was adjusted to a solution 
density corresponding to a solvent density of 1.019 g/ml by adding solid 
sodium bromide. A similar sequence of centrifugation followed by removal
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Fig. 2 - Flow charts for Isolation of serum lipoproteins by 
sequential preparative ultracentrifugation.
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of the supernatant fraction and adjustment of the solvent density of the 
infranatant portion to the next higher density was utilized to obtain the 
series of lipoprotein fractions, except that the fraction of d 1.210-1.250 
g/ml was isolated by ultracentrifugation for 44 hr at 103,000 x g.
Isolation of lipoprotein fractions of broader density ranges 
(Figure 2, schemes B and C) followed the procedure outlined above, except 
that 11 ml of serum per tube was adjusted to the appropriate solution den­
sity by adding solid sodium bromide. All lipoprotein fractions of d < 
1.110 g/ml (Figure 2, scheme B) were isolated by ultracentrifugation for 
22 hr, with the exception that in instances in which this segment of the 
lipoprotein spectrum was obtained in one step ultracentrifugation was 
repeated at the same density for an additional 22 hr (Figure 2, scheme C). 
The fraction of d 1.110-1.250 g/ml was isolated in either instance by 
centrifugation for 44 hr.
Samples of each lipoprotein fraction, as well as of the infra­
natant portion obtained at d 1.210 or 1.250 g/ml, were removed for lipid 
and immunochemical analyses. Lipid recoveries in the lipoprotein frac­
tions exceeded 80% of serum values. The remainder of each lipoprotein 
fraction was purified by resuspending the fraction in sodium bromide solu­
tion of appropriate density and centrifuging for 44 hr at 105,000 x g. 
After two washings, the lipoprotein fractions of d < 1.110 g/ml were found 
to be albumin-free by immunochemical analysis. One additional washing was 
necessary to provide an albumin-free preparation of fractions of d > 1.110 
g/ml. Samples of the purified lipoprotein fractions were obtained for 
lipid, protein and immunochemical analyses.
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Lipid Analysis
Lipoprotein fractions were extracted with a mixture of chloroform 
and methanol (2:1, v/v) according to the method of Folch and co-workers 
(187). The extract was evaporated in vacuo at room temperature, the lipid 
residue dissolved in chloroform and samples taken for lipid analyses. 
Cholesterol was determined by the Sperry and Webb modification (188) of 
the Schoenheimer-Sperry method. Lipid phosphorus was analyzed by the 
method of Fiske and Subbarow (189), after wet digestion by the procedure 
of Youngburg and Youngburg (190). The factor 25 was used to convert lipid 
phosphorus to "phospholipid". Triglyceride was determined by the method 
of Van Handel and Zilversmit (191), using tripalmitin as standard, or by 
the fluorometric method of Kessler and Lederer as applied to the Auto­
analyzer (192).
Protein Analysis 
Total protein in serum was determined by the biuret reaction 
(193). Serum protein fractions were separated by electrophoresis in a 
Beckman Microzone cell using cellulose acetate, stained with Ponceau S 
dye and quantitated by densitometric analysis in the Analytrol (Beckman 
Instruments, Inc.).
Protein in purified lipoprotein fractions was determined by the 
Lowry method (194), using canine serum albumin (Fraction V, Mann Research
Laboratories, Inc., New York, N. Y.) as standard.
Delipidization Procedures 
Samples of the purified lipoprotein fractions were dialyzed
against changes of 0.15 M sodium chloride for a minimum of 44 hr at 4° C.
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The dialyzed samples of HDL were then extracted with a mixture of ethanol 
and diethyl ether (3:1, v/v), followed by diethyl ether, according to the 
method of Scanu and co-workers (25) for total delipidization of lipopro­
teins. Partially delipidized lipoproteins were obtained using the method 
of Gustafson (195), in which lyophilized lipoprotein fractions are ex­
tracted repeatedly with n-heptane. After delipidization, the protein 
residue was dissolved in a buffer containing 0.1 M Tris-hydrochloride, 
pH 8, or borate, pH 9. Most of the protein present in HDL, but little 
of that in LDL, was recovered following total delipidization.
Preparation of Anti-Sera 
Rabbits were injected intraperitoneally with purified lipoprotein 
fractions, i.e., VLDL (1-5 mg of protein), LDL of d 1.019-1.063 g/ml (8- 
24 mg of protein) and HDL of d 1.110-1.210 or 1.160-1.210 g/ml (10-60 mg 
of protein), as well as totally delipidized HDL of d 1.110-1.210 g/ml (10 
mg of protein), mixed with complete Freund adjuvant (1:1, v/v). The rab­
bits were subsequently bled by cardiac puncture, usually at weekly inter­
vals, and received no additional antigen unless the first series of injec­
tions failed to induce antibody production within 6 weeks. After the ad­
dition of 0 .01% merthiolate, serum samples containing antibodies were di­
vided into small portions and stored frozen at -10° C. The following 
commercial anti-sera were also utilized: rabbit anti-canine serum and
anti-canine y-globulin (Mann Research Laboratories, Inc.), and rabbit 
anti-human serum, anti-human ai-lipoprotein and anti-human 6-lipoprotein 
(Hoechst Pharmaceutical Co., Kansas City, Mo.).
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Immunochemical Analyses 
Double diffusion in gel, according to the Ouchterlony method 
(196), was performed at room temperature in high humidity chambers, using 
plates prepared with 1% Difco special noble agar in Veronal buffer, pH 
8.6 , containing 0.01% merthiolate. Development of precipitin lines was 
observed for a period of 4 days, although the process was usually com­
pleted within 24 hr.
Immunoelectrophoresis on agar plates was performed in Veronal 
buffer, pH 8.6, at room temperature, using 190 V and 25 mA for 60 min, 
according to the technique of Grabar and Williams as modified for micro­
scopic slides by Scheidegger (197). Precipitin bands were recorded by 
direct photography of the plates and/or by staining of the immunoprecipi- 
tin lines for protein or lipid. Prior to staining, the plates were washed 
for 48 to 72 hr with several changes of 0.15 M sodium chloride and then 
distilled water. Lipids were stained with Oil Red 0 and protein with Amido 
Black B.
Gel Filtration Procedure 
Samples of Sephadex G-200 were equilibrated in a buffer solution 
containing 0.1 M Tris-hydrochloride and 0.15 M sodium chloride, pH 8.0.
This suspension was added to a 6-cm diameter column until a gel height of 
approximately 140 cm was attained. Lipoprotein fractions which had been 
dialyzed against the Tris-hydrochloride-sodium chloride buffer or serum 
samples were applied to the top of the gel and elution carried out at 4° C 
using the buffer solution. A flow rate of approximately 50 ml per hr was 
maintained and the eluate collected in 10.5-ml fractions. Each fraction 
was analyzed for optical density at 280 my using a Beckman Model DU spec-
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trophotometer. The fractions common to a segment of the protein elution 
pattern were combined and subjected to ultrafiltration on Millipore XM-50 
membranes (Millipore Filter Corp., Bedford, Mass.) as necessary to obtain 
uniform protein concentrations. Immunochemical analyses of each of the 
combined fractions were then performed.
Disc Electrophoresis 
Samples containing 0.1 to 0.4 mg of protein were applied to a 
standard gel, prepared from premixed solutions, containing 7% polyacryl­
amide, pH 8.9, in 5 X 76 mm tubes. Electrophoresis in 8 M urea was per­
formed using the Canalco Model 6 apparatus (Canal Industrial Corp., Rock­
ville, Md.), in which 5 mA per tube was applied for 30 min. Samples were 
stained either for lipid with Sudan Black B applied prior to electropho­
resis or for protein with Amido Black B applied after electrophoresis.
In several studies, reagents of the QDL-Kit (Canal Industrial Corp.) were 
used to permit comparison of results obtained with those from conventional 
lipoprotein analysis.
Amino Acid Analysis 
Lipoprotein samples containing approximately 2 mg of protein were 
hydrolyzed with 5.7 N HCl in evacuated tubes at 110° C for 24 hr or 72 hr. 
To each sample, 0.125 ymoles of norleucine was added as internal standard. 
The hydrolysates were extracted with chloroform three times to remove lip­
ids. Amino acids in the chloroform extracts were recovered by three wash­
ings with distilled water. These washings were combined with the lipid- 
free hydrolysate and evaporated to dryness ^  vacuo. The residue was re­
dissolved in 2 ml of 0.2 N citrate buffer, pH 2.2 and filtered through a
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sintered glass filter. Samples of the filtrate were obtained for amino 
acid analysis.
Chromatography of neutral and acidic amino acids was performed 
on a 52-cm column of Beckman ion exchange resin PA-28. Elution with 
Aminex citrate buffers (Bio-Rad Laboratories, Richmond, Calif.) was com­
pleted within 65 min (pH 3.25) or 105 min (pH 4.25). Basic amino acids 
were separated on a 6-cm column of Beckman ion exchange resin PA-35. Elu­
tion with Aminex citrate buffer was completed in 60 min (pH 5.28). The 
Beckman Model 120C amino acid analyzer was calibrated using an amino acid 
reference mixture. Values obtained in the 24-hr and 72-hr hydrolysates 
were extrapolated to zero time.
Metabolic Studies
Incorporation Studies
Each of the four dogs, after a 20-hr fast, was given intraven­
ously 175 pCi of L-lysine-U.L.-^^C (New England Nuclear Corp., Boston, 
Mass.). The ^^C-lysine used in all incorporation studies was obtained 
from a single lot. Blood samples, each of approximately 40 ml, were col­
lected before and at intervals of 0.5, 1, 2, 4, 8 and 12 hr after isotope 
injection. A small portion of the samples obtained at 0.5 and 12 hr was 
used for hematocrit determination. Lipoproteins and albumin were isolated 
from the remainder of these and all other samples. The dogs remained 
fasting throughout the study.
Lipoprotein fractions were isolated from the serum according to 
scheme B in Figure 2. Purified fractions of d 1.019-1.063 g/ml (LDL) and 
d 1.110-1.250 g/ml were subjected to total delipidization. The lipid-free
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protein residue was dissolved in 2 ml of 0.1 N NaOH and samples obtained 
for analysis of protein and radioactivity. Specific radioactivities were 
calculated as DPM per mg of protein.
Albumin was isolated from the infranatant fraction of d > 1.250 
g/ml, using the trichloroacetic acid-ethanol extraction procedure describ­
ed by Schwert (198). Proteins were precipitated with 10% trichloroacetic 
acid, washed twice with 5% trichloroacetic acid and extracted with 95% 
ethanol. The ethanol extract was dialyzed for 48 hr against several 
changes of 0.15 M sodium chloride and then distilled water. After remov­
ing a small amount of denatured protein by centrifugation, the albumin 
fraction was lyophilized, re-dissolved in 2 ml of 0.15 M sodium chloride 
and analyzed immunochemically. Samples were then obtained for determina­
tions of protein and radioactivity and specific radioactivity values cal­
culated, as described above.
Turnover Studies 
One of the male dogs used in earlier studies served as donor of 
biologically labeled proteins. While fasting, this dog was injected with 
5 mCi of L-lysine-U.L.-l^C and, after 6 hr, approximately 600 ml of blood 
was obtained for isolation of HDL and albumin.
The HDL fraction of d 1.110-1.250 g/ml was isolated according to 
scheme C in Figure 2 and purified. After dialysis for 48 hr against sev­
eral changes of 0.15 M sodium chloride, immunochemical analysis demon­
strated only HDL apolipoproteins, i.e., those producing A^-, A2- and A3- 
immunoreactions. Samples of the purified HDL fraction were obtained for 
determination of protein and radioactivity, as well as for delipidization 
with chloroform and methanol (2:1, v/v). Radioactivity in the lipid ex-
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tract represented less than 2% of the total lipoprotein radioactivity.
The remainder of the purified HDL fraction was administered to dogs in 
which turnover measurements were performed. Although it appears that HDL 
are relatively stable lipoproteins, this fraction was maintained at 4° C 
throughout the preparative procedures and re-injection was accomplished 
within 48 hr after completion of dialysis.
Albumin was isolated from the infranatant fraction of d > 1.250 
g/ml by the trichloroacetic acid-ethanol extraction procedure described 
above. After dialysis against 0.15 M sodium chloride, the albumin solu­
tion was found consistently to contain traces of apolipoprotein A. This 
contaminant was removed by gel filtration on a Sephadex G-200 column 
equilibrated with a buffer solution containing 0.1 M Tris-hydrochloride 
and 0.15 M sodium chloride, pH 8.0. The eluate containing albumin was 
concentrated by ultrafiltration on Millipore XM-50 membranes and then 
dialyzed against 0.15 M sodium chloride and distilled water. Immunochemi­
cal analysis of the purified albumin fraction demonstrated no evidence of 
apolipoproteins or other globulins. Samples of the purified albumin frac­
tion were obtained for protein and radioactivity analyses and for chloro- 
form-methano1 extraction. Less than 2% of the albumin fraction radioactiv­
ity was removed in the chloroform-methanol extract. The remainder of the 
purified albumin fraction was lyophilized and stored in a desiccator until 
re-injected.
A sample of the purified HDL fraction containing ^^C-labeled 
apolipoprotein (45 X 10^ DPM per kg; 20 X 10^ DPM per mg of protein) or 
purified l^C-labeled albumin (50 X 10^ DPM per kg; 6.9 X 10^ DPM per mg 
of protein) was injected intravenously over a 2-min interval into each of
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the four dogs following a 20-hr fast. Blood samples were collected before 
(45 ml) and at intervals of 10 and 20 min (5 ml each) and 0.5, 1, 1.5, 2, 
3, 4, 5, 6 and 7 days (40 ml each) after injection of the labeled protein. 
Lipoprotein fractions were isolated according to scheme C in Figure 2. In 
studies in which ^^C-labeled HDL were injected, the fractions of d < 1.110 
g/ml and d 1.110-1.250 g/ml were purified until albumin-free and then de­
lipidized, analyzed for protein and radioactivity and specific radioactiv­
ity calculated. The infranatant fraction of d > 1.250 g/ml was dialyzed 
against 0.15 M sodium chloride and analyzed for radioactivity. In studies 
in which ^^C-labeled albumin was administered, the infranatant fraction of 
d > 1.250 g/ml was used for isolation of albumin following procedures de­
scribed above.
Radioactivity Analyses 
Measurements were performed using the Packard Tri-Carb liquid 
scintillation spectrometer equipped with external standardization (Packard 
Instrument Co., Downers Grove, 111.). In the incorporation studies, 1 ml 
of NCS (Nuclear Chicago Corp., Des Plaines, 111.) and 15 ml of diluted 
Permafluor (Packard Instrument Co.) liquid scintillation solution were 
added to vials containing the sample in 0.2 ml of 0.1 N NaOH. In the 
turnover studies, a maximum of 1.0 ml of sample was added to vials con­
taining 20 ml of Gordon's scintillation mixture (199). Radioactivity 
values are presented as disintegrations per min (DPM).
Calculations
Radioactivity values were adjusted, where applicable, for the 
radioactivity removed in preceding blood samples during the course of a
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study. Data obtained in the turnover studies were not corrected, however, 
for re-incorporation of ^^C-lysine, since this must be negligible due to 
the relatively long turnover times of the proteins studied and to the ob­
servation that less than 2% of amino acids injected intravenously are re­
covered in plasma proteins (200).
Plasma volume (intravascular space) was calculated by the iso­
topic dilution technique using plasma radioactivity values at 10 min after 
injection of the labeled protein. Values were obtained by the equation: 
plasma volume (ml) = total radioactivity injected (DPM)/plasma radioactiv­
ity (DPM) per ml. Half time (T/2) was calculated from the exponential 
slope representing disappearance of protein radioactivity from plasma. 
Radioactivity values obtained between the third and seventh day were used 
in calculating this slope using a linear regression equation (201). The 
total volume of distribution (total exchangeable space) was estimated by 
extrapolating the disappearance curve of protein radioactivity in plasma 
to zero time, according to the method of Sterling (202). Turnover time 
(Tj.) was calculated by the formula 1.44 x T/2. The total exchangeable 
pool (i.e., "body pool", expressed as mg per kg body weight) of the pro­
tein was calculated using the total exchangeable space (ml), the serum 
concentration of the protein (mg per ml) and body weight (kg). The re­
placement rate (i.e., absolute turnover rate, expressed as mg per kg per 
day) was calculated by multiplying the total exchangeable pool by the 
fractional turnover time (l/T^, day“^).
Liver Function Tests
Bromsulphalein (Hynson, Westcott and Dunning, Inc., Baltimore, 
Md.) was injected intravenously at a dose of 5 mg per kg. Serum samples
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obtained after 15, 30 and 45 min were analyzed using the method of Rosen­
thal and White (203).
Bilirubin in serum was determined according to the method of 
Malloy and Evelyn, as modified by Kingsley and co-workers (204).
CHAPTER IV
RESULTS
Apolipoprotein and Lipid Composition of 
Serum Lipoprotein Fractions
Distribution of Serum Lipids in Lipoprotein Fractions
The percentage distribution of serum cholesterol, phospholipid 
and triglyceride among the lipoprotein fractions was obtained using re­
sults of lipid analyses of the fractions prior to purification and the 
results were corrected for the actual recovery (Table 3). Lipoproteins 
of d > 1.063 g/ml contained approximately 85% of the cholesterol and 90% 
of the phospholipid present in serum. Lipoproteins of d < 1.063 g/ml 
contained only 15% of the serum total cholesterol and 10% of the serum 
phospholipid, but more than 60% of the serum triglyceride. The corres­
ponding quantitative data are shown in Figure 3.
The lipid and protein composition of purified serum lipoprotein 
fractions is presented in Table 4. The content of protein increased and 
the ratio of phospholipid to protein decreased with increasing hydrated 
density of the lipoproteins.
Immunochemical Characterization of Purified 
Serum Lipoprotein Fractions
The apolipoproteins in purified lipoprotein fractions were in­
vestigated using anti-serum produced against purified canine serum lipo-
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TABLE 3
PERCENTAGE DISTRIBUTION OF SERUM LIPIDS IN CANINE LIPOPROTEIN FRACTIONS^
Lipoprotein Fraction (g/ml)






















































^Values are presented as the mean ± standard error. The lipoprotein fractions were isolated
U>
according to scheme A in Figure 2.
^Number of samples analyzed.
M G/100 ML SERUM
1 4 0 -
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Fig. 3 - Quantitative distribution of lipids in serum lipoprotein fractions,
TABLE 4
COMPOSITION OF PURIFIED CANINE SERUM LIPOPROTEIN FRACTIONS^
Lipoprotein No. of Percent of Protein and Lipids Phospholipid
Fraction Samples Protein Cholesterol Phospholipid Triglyceride Protein
VLDL
d < 1.006 3 12.3+4.4 9 .010.8 18.315.9 60.2110.7 1.5010.08
LDL
d 1.019-1.063 7 30.9±2.8 22.1+5.8 31.016.1 16.21 5.8 1.0210.21
HDL
d 1.063-1.110 10 34.8±3.4 19.613.5 37.713.5 7.91 3.6 1.1010.18
d 1.110-1.160 8 46.7±3.4 17.211.8 33.411.7 2.81 0.3 0.7210.08
d 1.160-1.210 8 50.2±1.4 12.811.1 34.312.1 2.71 0.7 0.6910.05
VHDL
d 1.210-1.250 — - - — 0.4710.09
^Values, presented as the mean ± standard error, are expressed as percent of the sum of the
weights of protein and lipids in each sample.




protein fractions. Each anti-serum preparation was characterized by the 
iimnunoprecipitin lines observed when reacted with canine serum, plasma or 
purified serum lipoprotein fractions (Table 5). Anti-serum obtained from 
rabbits given purified HDL fractions of d 1.110-1.210 g/ml or 1.160-1.210 
g/ml, when reacted with serum gave three immunoprecipitin lines, desig­
nated A^, A2 and A3 (Figure 4). In some cases a fourth immunoprecipitin 
line, designated A^, was also obtained. The Aj- and A^i-precipitin lines 
had ai-mobility on immunoelectrophoresis, while the Ag-line had a2-mobil- 
ity. The A%-precipitin reaction was observed as an arc which migrated 
toward the cathode.
Anti-serum obtained following the administration of purified 
LDL (d 1.019-1.063 g/ml) gave a single immunoprecipitin line, designated 
B, when reacted with serum. This reaction was characterized by immuno­
diffusion analyses as a line which, after 48 hr of development, appeared 
to have forked ends. During immunoelectrophoresis, the B-reaction mi­
grated as a diffuse immunoprecipitin arc to the ag- or g-region (the B- 
reaction resembled that obtained with anti-serum to purified VLDL shown 
in Figure 5).
Anti-serum to purified VLDL contained antibodies which reacted 
with serum to give the B- and A^-reactions and also a third immunopre­
cipitin line, the X-reaction (Figure 5). The X-precipitin line had an 02- 
migration on immunoelectrophoresis and in rare instances appeared as a 
double line. The X-precipitin reaction was non-identical to the A3- 
reaction.
Rabbit anti-canine serum gave a B-reaction and, in some prep­
arations, an A^-reaction when reacted with purified LDL or HDL. Rabbit
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TABLE 5
CHARACTERIZATION OF ANTI-SERA PRODUCED IN RABBITS IN RESPONSE 
TO PURIFIED CANINE SERUM LIPOPROTEIN FRACTIONS
Anti-Serum
Antigenic Components
Al A2 A3 Ax B X
anti-HDL^ + + + + - -
anti-LDL - - - - + -
anti-VLDL - - - + + +









Fig. 4 - A]̂ -, À2-, Ag- and A^-immunoprecipitin lines stained 
with Oil Red 0, demonstrating the presence of lipids.
Anti-HDL serum containing these antibodies was produced in 
rabbits following the administration of purified dog HDL.
Serum
Fig. 5 - A%-, B- and X-immunoprecipitin lines stained with Oil 
Red 0, demonstrating the presence of lipids.
Anti-VLDL serum containing these antibodies was produced in 
rabbits following the administration of purified dog VLDL.
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anti-canine y-globulin serum reacted with canine serum to produce at 
least two precipitin lines, one of which was the A%-reaction.
The distribution of apolipoproteins in purified lipoprotein 
fractions, as demonstrated by immunochemical analysis, is presented in 
Table 6. Precipitin lines characteristic of the A%-, B- and X-immuno- 
reactions were observed when purified VLDL was reacted with anti-VLDL 
(Figure 6). Although several purified LDL preparations gave only the 
B-reaction (Figure 7), evidence of apolipoprotein heterogeneity in the 
fractions isolated in the LDL density range was observed in analyses of 
other purified LDL preparations in which A- and X-reactions were also 
demonstrated (Figure 8).
Precipitin lines indicative of A^-, A2- and Ag-reactions were 
observed in purified HDL (Figure 9). The Ai-precipitin line, which was 
observed as the dominant reaction in this fraction, and the A2-reaction 
were demonstrated in all HDL preparations. The Aj-reaction could be dem­
onstrated only in instances in which the concentration of HDL in the 
preparation employed as antigen was similar to that in serum. Only the 
Al-precipitin line was detectable after dilution of HDL. Some purified 
HDL fractions of d 1.063-1.110 g/ml gave B- and X-reactions. In very 
rare instances, the X-precipitin line was also found in purified HDL of 
d 1.110-1.160 g/ml. The proportions of B- and X-reacting components de­
creased with increasing density, whereas the proportion of those charac­
terized by Al, A2 and A3 increased (Figure 10).
A3- and Ax-immunoreactions were demonstrated consistently in 
the infranatant portion obtained following ultracentrifugation of serum 










Fraction Al A2 A3 Ax B X
VLDL
d < 1.006 _ + + +
LDLb 
d 1.019-1.063 + ± - + ±
HDL
d 1.063-1.110 + + + ± +
d 1.110-1.160 + + + - -
d 1.160-1.210 + + + — — -
VHDL
d 1.210-1.250 + + + — — -
d > 1.250 - - + + -
Fresh serum 
or plasma + + + + + +
&The following symbols are used to indicate the immunoprecipi­
tin reactions observed: + = reaction demonstrated consistently; ± =
reaction demonstrated but not consistently; - = no reaction detected.
^The LDL fraction of d 1.006-1.019 g/ml contained very small 
amounts of lipoproteins which were insufficient for reliable analysis 




Fig. 6 - Iiranunoelectrophoretic analysis of purified VLDL demon­




Fig. 7 - Immunoelectrophoretic analysis of purified LDL.
Antibodies producing the B-immunoprecipitin reaction when re­









Fig. 8 - Immunodiffusion analysis of purified LDL preparations, 
demonstrating A- and X-reactions in addition to the characteristic B- 
reaction.
In parenthesis are the identification code numbers of rabbits 
from which the anti-sera were obtained.
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d < 1.110 g/ml




Fig, 9 - Immunoelectrophoretic analysis of purified HDL frac­

















Fig. 10 - Immunodiffusion analysis of purified HDL subfractions.
B- and X-reactions were demonstrated in the subfrattion of d 1.063-1.110 g/ml, but only a 
faint X-immunoprecipitin line in the subfraction of d 1.110-1.160 g/ml, in addition to the charac­
teristic A -reaction. The HDL subfraction of d 1.160-1.210 g/ml gave only the A-reaction. In paren­
thesis are the identification code numbers of rabbits from which the anti-sera were obtained.
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purified HDL preparations, as well as in the washings obtained during 
ultracentrifugal purification of HDL (Figure 11).
Each precipitin line was obtained with fresh serum or plasma. 
These precipitin lines generally reacted with Oil Red 0, except that in 
several instances the A%-line either failed to react or the positive re­
action was limited to its anodal end. Although delipidization of the 
lipoprotein fractions resulted in loss of reactivity with Oil Red 0, the 
immunoprecipitin reactions were clearly evident in all instances except 
for the B-reaction, which was not observed after total delipidization due 
to apparent very limited water solubility of apolipoprotein B.
Immunochemical Characterization of Lipoproteins 
Isolated by Gel Filtration
Two major peaks and one minor peak were observed when purified 
lipoproteins of d < 1.250 g/ml were separated by gel filtration on Sepha- 
dex G-200 (Figures 12 and 13). Immunochemical analyses of the lipopro­
teins in Fractions 1 and 2 eluted from the column demonstrated primarily 
a B-reaction, although Ai-, A2-, A3-, A^- and X-reactions were also ob­
served. Lipoproteins which exhibited Ai-, A2- and Ai-immunoreactions, 
but failed to give A^-, B- and X-reactions, were eluted in Fractions 4 
to 6. The immunologic characteristics of the lipoproteins eluted in the 
first peak are similar to lipoproteins of d < 1.110 g/ml, while the lipo­
proteins eluted subsequently resemble HDL of d > 1.110 g/ml.
When whole serum or lipoprotein-free serum, i.e., serum from 
which lipoproteins of d < 1.250 g/ml had been removed, was subjected to 
gel filtration, the first two of the three major peaks observed coincided 









5. d > 1.250 (1:100)
6. INFRANATANT FROM HDL PURIFICATION
Fig. 11 - Immunodiffusion analysis demonstrating the Ax-immuno-
reaction.
An identical A%-precipitin line was observed in fresh serum, 
purified VLDL, unpurified HDL, the washings obtained during purification 
of HDL and the serum sample from which lipoproteins of d < 1.250 g/ml had 
been removed. Antibodies producing the A%-reaction were present in anti- 
VLDL and anti-HDL serum.





















Fig. 12 - Immunodiffusion analysis of lipoprotein fractions separated by gel filtration on 
Sephadex G-200 column.
The albumin-free preparation of lipoproteins (d < 1.250 g/ml) applied to this column contained 
131 mg of protein. Elution volumes: prior to Fraction 1, 868 ml; Fractions 1-6 were 116, 95, 116, 
126, 137 and 116 ml, respectively (void volume, 952 ml).








Tig. 13 - Immunoelectrophoretic analysis of lipoprotein fractions separated by gel filtra­
tion on Sephadex G-200 column demonstrating Ax-reaction.
Identification of fractions can be seen on Fig. 12.
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lipoprotein fraction of d < 1.250 g/ml. Immunoreactions characteristic of 
Y-globulins were observed with the first and second major peaks, while al­
bumin was found in the third major peak. The immunoreactions of lipopro­
teins in the first two peaks obtained from whole serum were similar to 
those demonstrated in the corresponding peaks described in the preceding 
paragraph, with the exception that the Ax-reaction was also demonstrated 
in the second peak isolated from whole serum. Lipoprotein immunoreactions 
in the eluate obtained from lipoprotein-free serum were limited to an Ax- 
reaction in the first two peaks and almost negligible A%-, A2- and A3- 
reactions in the second peak.
Gel filtration of partially delipidized preparations of purified 
lipoprotein fractions indicated similar order of elution of apolipoprotein 
components as described above for native lipoproteins. However, after 
partial delipidization it was more apparent that the proportion of the 
Ag-reacting component, relative to the A%- and A^-components, increased 
in the fractions eluted later (Figure 14). The disc electrophoretic pat­
tern of these fractions in 7% polyacrylamide gel revealed several protein 
bands to which immunochemical characteristics of the fractions could be 
related only to a limited extent (Figure 15). Although differences among 
fractions in the proportions of the bands related to the A-antigenic com­
ponents could be observed, the bands did not appear to represent separated 
apolipoproteins of Ai-, A£- or Ag-antigenic components. Similar conclu­
sions were reached when intact or partially delipidized lipoprotein frac­
tions were subjected to disc electrophoresis using the larger pore-size 








Fig. 14 - Immunoelectrophoretic analysis of lipoprotein frac­
tions separated by gel filtration on Sephadex G-200 column.
A partially delipidized preparation of purified lipoproteins 
(d < 1.110 g/ml) was applied to the column. The first peak (I) eluted 
with the void volume. The fractions were subjected to immunoelectro­
phoresis in uniform protein concentration (1 mg/ml). Note the apparent 
differences between the proportions of apolipoprotein components charac­








Fig. 15 - Analytical polyacrylamide electrophoresis pattern of 
lipoprotein fractions separated by gel filtration on Sephadex G-200 
column.
Disc electrophoresis in 7% polyacrylamide gel, pH 8.9, contain­
ing 8 M urea; gels were stained with Amido Black lOB. After electro­
phoretic separation disc segments containing unstained gels were embedded 
in agar and subjected to immunochemical analyses.
Fractions I through IV are identified in Fig. 
tions gave the following immunoreactions:
14. These frac-
Al A2 A3 A% B X
Fraction I + + + + + -
Fraction II + + + + + +
Fraction III + + + - - +
Fraction IV + + + — _ —
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Effect of Methyltestosterone on the Apolipoprotein and 
Lipid Composition of Serum Lipoprotein Fractions
No change in body weight was observed during methyltestosterone 
administration and the dogs remained in good health throughout the study.
A relatively constant new low level of serum lipids was attained after 4 
weeks of methyltestosterone administration, although a downward trend was 
evident within 1 or 2 weeks. Changes in the opposite direction occurred 
at the same rate after the termination of treatment (Figure 16). Meth­
yltestosterone produced a statistically significant reduction (p < 0.001) 
in serum total cholesterol, phospholipid and triglyceride concentrations 
in each dog (Table 7). The cholesterol to phospholipid ratio was de­
creased by methyltestosterone to an average value of 86% of control. 
Methyltestosterone also lowered the apolipoprotein concentration to a 
mean value of 40% of control.
The concentrations of apolipoproteins and lipids were lower in 
all lipoprotein fractions during methyltestosterone administration (Figure 
17). This reduction was quantitatively greatest in the HDL fraction of 
d 1.110-1.250 g/ml, which comprises the major lipoprotein fraction in dog 
plasma.
The percentage distribution of apolipoproteins and lipids among 
the lipoprotein fractions is presented in Table 8. A greater proportion 
of each component, particularly cholesterol and triglyceride, was found 
in the fraction of d < 1.019 g/ml during methyltestosterone administra­
tion. Methyltestosterone also increased the proportion of total serum 
triglyceride found in the LDL fraction, but decreased the proportions of 
total apolipoprotein, cholesterol and phospholipid. The HDL fraction of 






Fig. 16 - Effect of methyltestosterone treatment on serum lipid levels.
CT\Co
C = control period, MT = methyltestosterone treatment. 100% = serum lipid levels of each 
dog during the first control period. Shaded area = mean ± standard error of four dogs in steady state 
condition. Solid and dotted lines = transitory periods between two steady states with or without 
lipid determinations, respectively.
TABLE 7
BODY WEIGHT AND APOLIPOPROTEIN AND LIPID CONCENTRATIONS IN CANINE SERUM 
LIPOPROTEINS BEFORE AND DURING METHYLTESTOSTERONE ADMINISTRATION^
Dog Body Weight
Lipoprotein Components (mg/100 ml)
(kg) Cholesterol Phospholipid Triglyceride Protein^
104 (Male)
Control















































































^Values presented are the mean ± standard error.
^Apolipoprotein values were calculated using the phospholipid :protein ratio for the purified 
lipoprotein fractions (see Table 9).
^Number of observations or analyses.
^Statistical significance of difference between values obtained during control and methyl­
testosterone treatment periods is indicated (n.s. = not significant, i.e., p ^  0.05).
m g / 1 0 0  m l  S E R U M
400-1
3 0 0 - C O N T R O L
M E T H Y L T E S T O S T E R O N E
200-
100-
^  PR C PL TG PR C PL TG PR C PL TG ^R C PL TG
<1.019 1.019-1.063 1.063-1.110 1.110-1.250
DENSITY RANGE (g/ml)
C PL TG 
>1.250
Ln
Fig. 17 - Quantitative changes in apolipoproteins and lipids in serum lipoprotein fractions 
produced by methyltestosterone treatment.
PR = protein, C = cholesterol, PL = phospholipid, TG = triglyceride.
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TABLE 8
EFFECT OF METHYLTESTOSTERONE ON PERCENTAGE DISTRIBUTION 























Me thy1tes tos terone - l.OiO.l
Difference n.s.
*Values from the four dogs are presented as the mean ± standard
error.
^Apolipoprotein values were calculated using the phospholipid 
concentration in the unwashed lipoprotein fraction and the phospholipid 
to protein ratio of the purified lipoprotein fraction. The protein con­
tent in the lipoprotein fraction is presented as a percentage of the 
total amount recovered in the fractions of d < 1.250 g/ml.
*The content of each lipid in the unwashed lipoprotein fraction 
is presented as a percentage of the total amount of that lipid recovered 
in all fractions.
•^Statistical significance of difference between.values obtained 
during control and methyltestosterone treatment periods is indicated 












n.s. p < 0.01
60.3+2.0 28.4+2.7
65.0+2.6 12.9±1.1
n.s. p < 0.01
6.5+0.6 1.810.1
6.9+0.7 8.2+2.0
n.s. p < 0.02
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lipoprotein, cholesterol and phospholipid. The HDL fraction of d 1.063- 
1.110 g/ml contained a slightly greater portion of the total apolipopro- 
teins in serum lipoproteins during methyltestosterone administration, but 
less of the total serum triglyceride was found in this fraction. Methyl­
testosterone increased slightly the proportions of cholesterol and phos­
pholipid contained in the principal plasma lipoprotein fraction, i.e., 
the HDL fraction of d 1.110-1.250 g/ml, and decreased the proportion of 
total serum triglyceride. The proportions of total serum cholesterol 
and phospholipid remaining in the d > 1.250 g/ml fraction was essentially 
unchanged by methyltestosterone. Although a statistically significant 
increase was found in the proportion of total serum triglyceride con­
tained in the d > 1.250 g/ml fraction, this observation should be inter­
preted with caution inasmuch as the amounts of triglyceride available in 
this fraction for analysis were very small and hence the accuracy of 
these determinations may be questioned.
Results presented in Table 9 demonstrate that the apolipoprotein 
represented relatively less of each lipoprotein fraction during methyltes­
tosterone administration. The phospholipid to protein ratio increased in 
all but the d < 1.019 g/ml fraction. Triglyceride constituted a greater 
proportion of those lipoproteins of d < 1.110 g/ml during methyltestoster­
one administration.
The purified lipoprotein fractions obtained from each dog during 
the control period gave similar immunoprecipitin reactions to those de­
scribed in the preceding section of this Chapter. The purified HDL frac­
tion of d 1.110-1.250 g/ml gave A^-, A2- and Ag-reactions. A%- and A2- 
reactions were the major precipitin lines found in the purified HDL frac-
TABLE 9
EFFECT OF METHYLTESTOSTERONE ON COMPOSITION OF 
PURIFIED SERUM LIPOPROTEIN FRACTIONS^
Lipoprotein Fraction
Percent of Lipoprotein Components Phospholipid
Protein Cholesterol Phospholipid Triglyceride Protein
d < 1.019
Control 15.2±1.8 7.211.2 22.414.7 55.316.2 1.5010.36
Methyltestosterone 10.9±2.7 9.511.2 14.012.1 65.715.1 1.4510.25
d 1.019-1.063
Control 31.511.7 20.314.2 27.713.0 20.616.8 0.8810.09
Methyltestosterone 25.316.2 15.412.8 26.612.8 32.715.6 1.2810.35
d 1.063-1.110
Control 38.314.0 18.311.8 36.613.5 6.811.5 1.0210.19
Methyltes tos terone 34.917.6 17.115.4 32.718.3 10.613.4 1.1210.37
d 1.110-1.250
Control 55.112.7 12.511.0 30.312.1 2.210.3 0.5610.06
Methyltestosterone 52.210.4 12.210.5 33.810.8 1.810.2 0.6510.02
o\VO
^Values from the four dogs are presented as the mean ± standard error. In each instance the 
difference between values obtained during control and methyltestosterone periods is not statistically 
significant, i.e., p ^  0.05.
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tion of 1.063-1.110 g/ml. In addition, a minor immunoprecipitin line 
characteristic of the B-reaction was observed in the HDL fraction of d 
1.063-1.110 g/ml in each dog. The X-reaction was also demonstrated in 
this fraction from Dog 104. The purified LDL fraction gave a B-reaction, 
as well as A- and X-reactions representing minor immunoprecipitin lines. 
The purified fraction of d < 1.019 g/ml gave a B-reaction and a less in­
tense X-reaction. Individual variations in the proportions of the apoli- 
poproteins present in the purified lipoprotein fraction of d < 1.110 g/ml 
are shown in Figure 18. Methyltestosterone reduced the intensity of the 
A-reactions. Although apparent in the immunoprecipitin reaction of the 
HDL fraction, this response to methyltestosterone was most obvious in the 
marked diminution of the A-reaction in the purified LDL fraction (Figure 
19). Proportionate changes in the B- and X-reactions were not observed.
Analysis of the amino acid composition of apolipoproteins in the 
purified HDL fraction of d 1.110-1.250 g/ml suggested no significant qual­
itative change in the protein in response to methyltestosterone adminis­
tration (Table 10). Although some values for a few amino acids were dif­
ferent before and during methyltestosterone treatment, this observation 
should be interpreted with caution inasmuch as the values represented sin­
gle determinations. Similar analyses were not attempted on other lipopro­
tein fractions due to the apolipoprotein heterogeneity of these fractions.
Methyltestosterone had no effect on total serum protein concen­
tration (Table 11). Nevertheless, methyltestosterone produced a signifi­
cant increase in albumin and a decrease in the aj- and 3-globulin frac­
tions. Neither bromsulphalein retention nor serum bilirubin concentra­















Dog 181 Dog 233 Dog 236
Fig. 18 - Immunodiffusion analysis of the purified serum lipoprotein fraction of d < 1.110 
g/ml of the four dogs in which methyltestosterone studies were performed.
The fractions were isolated according to scheme C in Fig. 2. The concentration of the puri­
fied fractions was 4 mg/ml. Note the individual variations in apolipoprotein components by comparing 
the relative positions and intensities of the A-, B- and X-immunoprecipitin lines. In the analyses 
presented, the failure to demonstrate an A-precipitin line in reactions with well number 6 for Dog 104 
and with wells number 3 and 4 in each dog is due to excessive antigen in relation to antibody concen­
tration.













Fig. 19 - Immunodiffusion analysis of purified LDL fractions demonstrating the marked diminu­
tion of the A-precipitin line, relative to the B-line, during methyltestosterone treatment.
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TABLE 10
EFFECT OF METHYLTESTOSTERONE ON AMINO ACID 
COMPOSITION OF HDL APOLIFOPROTEINS®
Control Methyltestosterone
iilUXUU A c x a
(104 & 181)b (233 & 236) (104 & 181) (233 & 236)
Alanine 78.8 89.0 83.7 88.1
Arginine 46.7 40.3 50.5 40.8
Aspartic acid 71.1 74.6 70.2 74.2
Cystine/2 0.0 0.0 0.0 tr.
Glutamic acid 164.4 171.2 167.5 173.7
Glycine 41.9 41.6 37.0 36.1
Histidine 8.3 0.0 7.2 4.4
Isoleucine 6.6 6.9 7.2 8.5
Leucine 112.3 117.3 112.8 126.3
Lysine 45.3 48.4 47.9 37.6
Methionine 3.5 2.3 3.0 3.3
Phenylalanine 14.8 14.4 15.5 15.7
Proline 32.5 33.5 36.7 33.8
Serine 61.4 49.5 47.1 44.1
Threonine 29.2 25.4 24.3 23.4
Tyrosine 16.6 17.7 17.8 17.7
Valine 41.9 47.0 42.3 47.9
^Analyses were performed in the HDL fraction of d 1.110-1.250 
g/ml. Values are presented as moles per 100,000 g of protein. Trypto­
phan analyses were not performed.
^HDL samples obtained from the dogs identified in parentheses 
were combined for analyses.
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TABLE 11
EFFECT OF METHYLTESTOSTERONE ON CONCENTRATION 
OF SERUM PROTEIN FRACTIONS^
Protein Fractions Control Methyltestosterone Difference^
Albumin 2.63±0.09 3.47+0.11 P < 0.01
oil-Globulin 0.34+0.01 0.29+0.01 P < 0.02
a2-Globulin 0.64+0.08 0.67+0.07 n.s.
g-Globulin 2.79+0.29 1.94±0.13 P < 0.05
y-Globulin 0.68+0.09 0.73±0.07 n.s.
Total protein 7.08±0.24 7.1010.15 n.s.
^Values (g/100 ml) for the four dogs are presented as mean ± 
standard error. The value used for each dog represented the average of
at least 11 determinations in each period.
^Statistical significance of difference between values obtained 
during control and methyltestosterone periods (n.s. = not significant, 
i.e., p > 0.05).
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Effect of Me thyl tes tos terone on the Incorporation of ^'^C-Lysine 
Into the Apolipoproteins of Serum HDL and LDL and 
Serum Albumin and on the Turnover of 
HDL-Apolipoprotein and Albumin
Additional studies were undertaken to evaluate the effect of 
methyltestosterone on the metabolism of apolipoprotein A, i.e., the apo­
lipoprotein of HDL and the dominant apolipoprotein in canine plasma.
These studies were performed using purified HDL of d 1.110-1.250 g/ml, 
inasmuch as results presented above indicated that this fraction contained 
the majority of apolipoprotein A but no apolipoprotein B or X. lysine
incorporation was also measured in LDL, a heterogeneous lipoprotein frac­
tion containing apolipoproteins A, B and X. Similar studies were perform­
ed using albumin, which provided a reference for evaluating the effects of 
methyltestosterone on protein metabolism.
Incorporation Studies
The serum concentrations of LDL (d 1.019-1.063 g/ml) and HDL (d
1.110-1.250 g/ml) apolipoproteins and albumin during control and methyl­
testosterone periods are presented in Table 12. Methyltestosterone de­
creased the concentration of LDL and HDL apolipoproteins and increased 
albumin. The sum of the concentrations of these three proteins increased, 
however, due to the magnitude of the increase in albumin. Since the con­
trol and methyltestosterone periods represented steady states in which the 
pool sizes of these proteins differed significantly, results from the in­
corporation studies were calculated as total radioactivity (DPM per 100 ml 
of serum) by multiplying specific radioactivity values by the appropriate 
protein concentration obtained from Table 12.
Values representing the sum of total radioactivities incorporated
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TABLE 12
CONCENTRATION OF LDL AND HDL APOLIPOPROTEINS 





Control 53 360 2,530
Methyltestosterone 6 181 3,520
Dog 181
Control 31 316 2,760
Methyltestosterone 15 140 3,420
Dog 233
Control 36 329 2,790
Methyltestosterone 4 119 3,740
Dog 236
Control 43 390 2,440
Methyltestosterone 8 144 3,200
^Values are expressed as mg per 100 ml of serum.
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into LDL and HDL apolipoproteins and albumin are presented in Figures 20- 
23. Maximal levels were attained within 8 hr after precursor injection. 
Results obtained for individual proteins were calculated as a percentage 
of the maximal radioactivity incorporated into the three proteins in each 
study. Results presented in Figures 20-23 demonstrate that the greatest 
proportion of radioactivity was incorporated into albumin and the least 
into LDL apolipoprotein. Methyltestosterone reduced the proportion in 
HDL and LDL apolipoproteins, while that in albumin was increased (Table 
13).
Comparison of results obtained in individual studies was also fa­
cilitated by calculating the incorporation data for apolipoproteins rela­
tive to albumin. Results presented in Table 14 indicate that the HDL: al­
bumin ratio was maximal at 0.5 hr after isotope injection, then declined 
to a level which remained relatively constant. A similar pattern was ob­
served during control and methyltestosterone periods. Methyltestosterone 
reduced this ratio to less than 50% of control.
Turnover Studies
Radioactivity in serum and in fractions of d < 1.110 g/ml, d
1.110-1.250 g/ml (HDL) and d > 1.250 g/ml was measured at intervals up to 
7 days. A significant portion of the radioactivity administered as l^C- 
apolipoprotein A in HDL of d 1.110-1.250 g/ml was subsequently recovered 
in the lipoprotein fraction of d < 1.110 g/ml (control period) or in the 
latter fraction and the fraction of d > 1.250 g/ml (methyltestosterone 
period) (Table 15). The re-distribution of radioactivity appeared to be 
time-dependent, i.e., the decrement in radioactivity in the HDL fraction 
was associated with a progressive increment in radioactivity in other
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Fig. 20 - Time course and relative rate of ^'^C-lysine incorporation into LDL and HDL apolipo­
proteins and albumin.
Abscissa: time in hr after precursor injection; ordinate: percent of the sum of maximal
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Fig. 21 - Time course and relative rate of ^'^C-lysine incorporation into LDL and HDL apolipo­
proteins and albumin.
Abscissa: time in hr after precursor injection; ordinate: percent of the sum of maximal
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Fig, 22 - Time course and relative rate of lysine incorporation into LDL and HDL apolipo­
proteins and albumin.
Abscissa; time in hr after precursor injection; ordinate: percent of the sum of maximal
radioactivities incorporated into the three proteins.
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Fig. 23 - Time course and relative rate of ^^C-lysine incorporation into LDL and HDL apolipo­
proteins and albumin.
Abscissa: time in hr after precursor injection; ordinate: percent of the sum of maximal
radioactivities incorporated into the three proteins.
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TABLE 13
RATE OF INCORPORATION OF LYSINE-l^C INTO LDL AND HDL 
APOLIPOPROTEINS AND ALBUMIN BEFORE AND DURING 
METHYLTESTOSTERONE TREATMENT^




Control 1.3+0.9 4.3+3.1 3.9+2.5
Methyltestosterone 0.2 0.4 0.6+0.4
Difference^ — - n.s.
HDL
Control 7.9+1.4 14.4+2.0 19.1+2.2
Methyltestosterone 4.2+0.7 6.8+0.2 11.2±1.0
Difference n.s. p < 0.001 p < 0.02
Albumin
Control 13.1+1.6 38.2+2.2 55.3+1.1
Methyltestosterone 17.0+2.7 47.8±3.2 72.3+3.3
Difference n.s. p < 0.05 p < 0.01
Sum of the above
Control 22.3+1.9 56.9+1.5 78.2+3.1
Methyltestosterone 17.8+6.2 55.5+4.5 83.9+2.7
Difference n.s. n.s. n.s.
^Values are presented as mean ± standard error in the four
dogs, of the percent of maximum protein radioactivity incorporated into 
each protein. The total radioactivity incorporated into the three pro­
tein components at 8 and 12 hr after lysine-l^C injection was averaged 
and assigned the value of 100%, i.e., the maximum protein radioactivity. 
The mean ± standard error of these values in the four dogs was 574±44 x 
1q3 DPM per 100 ml of serum.
^Statistical significance of difference between values obtained 
before and during methyltestosterone treatment is indicated (n.s. = not 






n.s. n.s. p < 0.05
22.8+2.5 25.6+1.2 25.7+1.5
13.8+1.8 15.5+2.1 13.3+0.8
p < 0.05 p < 0.01 p < 0.001
62.3+1.9 66.3+1.2 66.1+2.7
82.4+1.6 82.3+2.1 86.0+2.4





EFFECT OF METHYLTESTOSTERONE ON HDL;ALBUMIN RATIO OF 
RADIOACTIVITY INCORPORATED FROM l^C-LYSINE
Hours after Lysine-l^C Injection
oog
0.5 1.0 2.0 4.0 8.0 12.0
104 0.52 0.32 0.27 0.27 0.34 0.35
181 0.47 0.31 0.30 0.37 0.43 0.39
I—1o 233 0.65 0.40 0.38 0.38 0.39 0.34
ug 236 0.72 0.46 0.43 0.45 0.38 0.48o Mean 0.59 0.37 0.35 0.37 0.39 0.39
±S.E. ±0.06 ±0.04 ±0.04 ±0.04 ±0.02 ±0.03
104 0,29 0.16 0.15 0.15 0.15 0.14
1 181 0.22 0.15 0.13 0.14 0.14 0.18
CD <U
0) 0 O 233 0.18 0.12 0.13 0.15 0.19 0.141-1 l-l>> <u43 4J 236 0.34 —  — 0.22 0.24 0.28 -44 CD 
0) O
S  4-» Mean 0.26 0.14 0.16 0.17 0.19 0.15
+S.E. ±0.04 ±0.01 ±0.12 ±0.02 ±0.03 ±0.01
Difference^ p < 0.001 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.001
00
^Statistical significance of difference between mean values for control and meth— 
yltestosterone periods is indicated (n.s. = not significant, i.e., p ^  0.05).
TABLE 15
EFFECT OF METHYLTESTOSTERONE ON PERCENTAGE DISTRIBUTION OF 
RADIOACTIVITY RECOVERED IN LIPOPROTEIN FRACTIONS^
Lipoprotein Days after Injection of HDL(l^C-Apolipoprotein)
Fractions 0.5 1.0 1.5 2.0 3.0 4.0 5.0 6.0 7.0
ou
A~icou
d < 1.110 
d 1.110-1.250 
d > 1.250
19 23 27 30 44 52 50 69 66
81 77 73 70 56 48 50 31 34
ooLn
0 0 0 0 0 0 0 0 0
I
CO 0) (U G
^  s
4-1 CO(U o S -U
d < 1.110 0 2 0 0 2 9 17 23 20
d 1.110-1.250 94 92 88 90 77 67 60 48 68
d > 1.250 6 6 12 10 21 24 23 29 12
^Values, expressed as percent of total serum radioactivity recovered in individual frac­
tions , are presented as the mean for the four dogs studied.
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fractions. Individual variations were observed among the four dogs in 
respect to the proportion of total serum radioactivity recovered in the 
HDL fraction relative to that found in the d < 1.110 g/ml fraction. In 
studies during the control period in Dogs 233 and 236, the HDL fraction 
and the fraction of d < 1.110 g/ml each contained about 50% of the serum 
radioactivity at 7 days, whereas the HDL fractions contained less than 
35% of total serum radioactivity in Dog 181 and less than 20% in Dog 104, 
i.e., the majority of serum radioactivity in Dogs 104 and 181 was present 
in the lipoprotein fraction of d < 1.110 g/ml. The appearance of radio­
activity in the fraction of d < 1.110 g/ml was delayed during methyltes­
tosterone administration.
Control values for the rate of disappearance of radioactivity 
from the HDL fraction (T/2 = 2.28±0.08 days) (Figures 24-27, Table 16) 
were less than in serum (T/2 = 4.74±0.97 days) (Figures 28-31, Table 17). 
Methyltestosterone treatment resulted in an increased half time of apo­
lipoprotein A in the HDL fraction to a mean of 3.50±0.61 days, while the 
value in serum was decreased to a mean of 3.52±0.32 days. The control 
turnover rates for apolipoprotein A in the HDL fraction were similar in 
the four dogs (Table 16). When compared with these values, two of the 
control turnover rates for apolipoprotein A in serum were less and two 
were greater (Table 17). The lower values were observed in Dogs 104 and 
181, in which 65 to 80% of the labeled apolipoprotein A was present in 
lipoproteins of d < 1.110 g/ml at 7 days, compared with approximately 50% 
in this fraction in Dogs 233 and 236. Turnover rates were significantly 














Fig. 24 - Disappearance of ^^C-apolipoprotein A from HDL (d 1.110-1.250 g/ml) fraction of
serum.
14.Abscissa; time in days after injection of HDL containing C-apolipoprotein (d 1.110-1.250 
g/ml); ordinate: logarithm of the percent of initial specific radioactivity of apolipoprotein A.
The initial specific radioactivity (specific radioactivity at zero time, in DPM per mg of protein) 
was calculated using the values for injected radioactivity and for the intravascular pool of apo­
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Fig. 25 - Disappearance of apolipoprotein A from HDL (d 1.110—1.250 g/ml) fraction of
serum.
Abscissa: time in days after injection of HDL containing C-apolipoprotein (d 1.110-1.250
g/ml); ordinate: logarithm of the percent of initial specific radioactivity of apolipoprotein A.
The initial specific radioactivity (specific radioactivity at zero time, in DPM per mg of protein) 
was calculated using the values for injected radioactivity and for the intravascular pool of apo­
lipoprotein A in HDL (d 1.110-1.250 g/ml).
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Fig. 26- Disappearance of ^^C-apolipoprotein A from HDL (d 1.110-1.250 g/ml) fraction of
serum.
Abscissa: time in days after injection of HDL containing I'^C-apolipoprotein (d 1.110—1.250
g/ml); ordinate: logarithm of the percent of initial specific radioactivity of apolipoprotein A.
The initial specific radioactivity (specific radioactivity at zero time, in DPM per mg of protein) 
was calculated using the values for injected radioactivity and for the intravascular pool of apo­
lipoprotein A in HDL (d 1.110-1.250 g/ml).
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Fig. 27 - Disappearance of ^^C-apolipoprotein A from HDL (d 1.110—1.250 g/ml) fraction of
serum.
Abscissa: time in days after injection of HDL containing l^C-apolipoprotein (d 1.110-1.250
g/ml); ordinate: logarithm of the percent of initial specific radioactivity of apolipoprotein A.
The initial specific radioactivity (specific radioactivity at zero time, in DPM per mg of protein) 
was calculated using the values for injected radioactivity and for the intravascular pool of apo­
lipoprotein A in HDL (d 1.110-1.250 g/ml).
TABLE 16
EFFECT OF METHYLTESTOSTERONE ON HALF TIME, TURNOVER RATE AND 
TOTAL EXCHANGEABLE POOL OF APOLIPOPROTEIN A 













104 3.18 2.28 76.6 100.0 77.7 247.0
181 2.91 2.08 67.1 100.0 69.9 203.4
1—4O 233 3.02 2.32 63.5 100.0 70.1 211.8
Ug 236 1.81 2.45 70.3 100.0 138.6 250.9o
Mean 2.73 2.28 69.4 100.0 89.1 228.3
±S.E. ±0.31 ±0.08 ±2.8 ±0.0 ±16.6 ±12.1
104 0.97 4.18 13.6 17.8 82.5 80.1
1CO ai 181 0.96 4.85 9.8 14.6 73.1 70.1
Qj (3 •u o 
•— 1 w 233 0.60 2.69 11.9 18.7 76.1 45.7
>. 0) 
j z  u 236 0.83 2.26 14.9 21.2 57.8 48.0
mai o
Mean 0.84 3.50 12.6 18.1 72.4 61.0
±S.E. ±0.09 ±0.61 ±1.1 ±1.4 ±5.2 ±8.4
Difference^ p < 0.01 n.s. p < 0.001 p < 0.001 n.s. p < 0.001
^Statistical significance of difference between mean values for control and methyltestoster- 
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Fig. 28 - Disappearance of ^^C-apolipoprotein A from serum.
Abscissa: time in days after injection of HDL containing ^^C-apolipoprotein (d 1.110-1.250












Fig. 29 - Disappearance of ^^C-apolipoprotein A from serum.
Abscissa: time in days after injection of HDL containing l^C-apolipoprotein (d 1.110-1.250
irdi : logarithm of the percent of initial serum radioactivity.
DOG 233










Fig. 30 - Disappearance of apolipoprotein A from serum.
Abscissa: time in days after injection of HDL containing l^C-apolipoprotein (d 1.110-1.250



















Fig. 31 - Disappearance of ^^C-apolipoprotein A from serum.
Abscissa: time in days after injection of HDL containing ^^C-apolipoprotein (d 1.110-1.250
g/ml); ordinate: logarithm of the percent of initial serum radioactivity.
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TABLE 17
EFFECT OF METHYLTESTOSTERONE ON HALF TIME, TURNOVER RATE AND 
EXCHANGEABLE POOLS OF APOLIPOPROTEIN A IN SERUM





(mg/kg/day) % of Control
104 4.88 6.84 36.6 100.0
181 3.88 5.79 43.1 100.0
iH
O 233 4.51 2.55 89.7 100.0
g 236 4.73 3.76 92.9 100.0u
Mean 4.50 4.74 65.6 100.0
±S.E. ±0.22 ±0.97 ±14.9 ±0.0
104 2.53 4.43 30.7 83.9
1 181 1.84 3.42 22.3 51.7
CO (U
0) pi ■u) o 233 1.70 2.95 30.8 34.3
H  M>. OJ 
J S -w 236 2.15 3.27 36.0 38.8
W  CO 
0) 0
Mean 2.06 3.52 30.0 52.2
+S.E. ±0.18 ±0.32 ±2.8 ±11.2
Difference^ p < 0.001 n.s. n.s. p < 0.01
^These values were approximated as the apolipoprotein concen­
tration in the HDL fraction of d > 1.063 g/ml.
Statistical significance of the difference between mean values 
for control and methyltestosterone periods is indicated (n.s. = not sig­
nificant, i.e., p > 0.05).
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TABLE 17— Continued













73.5 358.6 32.0 156.1 43.5 56.5
92.6 359.3 30.7 119.1 33.2 66.8
73.1 329.7 29.7 133.9 40.6 59.4
106.2 502.5 40.4 191.1 38.0 62.0
86.4 387.5 33.2 150.1 38.8 61.2
±8.0 ±38.9 ±2.4 ±15.7 ±2.2 ±2.2
77.3 195.5 43.5 110.1 56.3 43.7
59.7 109.8 43.3 79.7 72.5 27.5
77.0 130.9 44.2 75.1 57.4 42.6
79.2 170.2 56.2 120.4 71.0 29.0
73.3 151.6 46.8 96.3 64.3 35.7
±4.6 ±19.3 ±3.1 ±11.2 ±4.3 ±4.3
n.s. p < 0.001 p < 0.02 p < 0.05 p < 0.01 p < 0.01
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Values for total exchangeable pool of apolipoprotein A in the 
HDL fraction (Table 16) are less than those for apolipoprotein A in whole 
serum (Table 17). This discrepancy is attributable to differences in se­
rum concentrations, i.e., the amount of apolipoprotein A in the HDL frac­
tion represents only a portion of that in serum. However, values for to­
tal exchangeable space of apolipoprotein A, calculated by two methods, 
gave similar results. Methyltestosterone reduced the mean total exchange­
able pool for apolipoprotein A to less than 50% of control. This change 
reflects a greater loss from the extravascular pool than from the intra­
vascular pool (Table 17).
Measurements of albumin radioactivity were performed for 7 days 
following injection of purified ^'^C-albumin. Radioactivity disappeared 
from the plasma during the control period with a rate representing a mean 
half time of 16.26±2.84 days (Figures 32-35, Table 18). This value was 
reduced to 8.23±0.78 days during methyltestosterone administration. Fur­
thermore, methyltestosterone increased the total exchangeable pool for 
albumin by almost 50%. These changes in albumin metabolism are reflected 
in an almost three-fold increase in turnover rate during methyltestoster­
one treatment. Results presented in Table 18 also indicate that the in­
crease in total exchangeable albumin produced by methyltestosterone repre­
sented equivalent increments in the intravascular and extravascular pools.
Measurements of the intravascular space (plasma volume) using HDL 
containing ^^C-apolipoprotein (Table 17) gave somewhat lower values than 
were obtained with ^^C-albumin (Table 18). These values were increased 













Fig. 32 - Disappearance of l^C—albumin from serum.
Abscissa: time in days after injection of l^C-albumin; ordinate: logarithm of the percent
of initial specific radioactivity of albumin. The initial specific radioactivity (specific radioactiv­
ity at zero time, as DPM per mg of protein) was calculated using values for injected radioactivity and 
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Fig. 33 - Disappearance of ^^C-albumin from serum.
Abscissa: time in days after injection of l^C-albumin; ordinate: logarithm of the percent
of initial specific radioactivity of albumin. The initial specific radioactivity (specific radioactiv­
ity at zero time, as DPM per mg of protein) was calculated using values for injected radioactivity and 
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Fig. 34 - Disappearance of l^C-albumin from serum.
Abscissa: time in days after injection of l^C-albumin; ordinate: logarithm of the percent
of initial specific radioactivity of albumin. The initial specific radioactivity (special radioactiv­
ity at zero time, as DPM per mg of protein) was calculated using values for injected radioactivity and 
for the intravascular pool of albumin.
DOG 236
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Fig. 35 - Disappearance of 1‘̂ C-albumin from serum.
Abscissa; time in days after injection of l^C-albumin; ordinate: logarithm of the percent
of initial specific radioactivity of albumin. The initial specific radioactivity (specific radioactiv­
ity at zero time, as DPM per mg of protein) was calculated using values for injected radioactivity and 
for the intravascular pool of albumin.
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TABLE 18
EFFECT OF METHYLTESTOSTERONE ON HALF TIME, TURNOVER RATE AND 
EXCHANGEABLE POOLS OF ALBUMIN





(mg/kg/day) % of Control
104 29.0 9.12 249.8 100.0
181 28.1 14.33 136.8 100.0
HO 233 28.1 20.07 113.2 100.0
■U0 236 28.0 21.50 109.7 100.0
Ü
Mean 28.3 16.26 152.4 100.0
+S.E. ±0.2 ±2.84 ±33.0 ±0.0
104 33.5 7.00 610.3 244.3
1CO 0) 181 32.9 7.17 332.5 243.10) G 
2 233 32.2 10.38 285.4 252.1
236 28.5 8.36 374.8 341.7
2 Mean 31.8 8.23 400.8 270.3
+S.E. ±1.1 ±0.78 ±72.2 ±23.9
Difference^ p < 0.05 p < 0.05 p < 0.05 p < 0.001
^Statistical significance of difference between mean values for 
control and methyltestosterone periods is indicated (n.s. = not signifi­
















113.3 3286.9 55.3 1603.4 48.8 51.2
101.5 2851.4 49.1 1351.4 48.4 51.6
115.1 3234.3 57.0 1601.1 49.5 50.5
122.4 3428.1 59.7 1672.2 48.8 51.2
113.1 3200.2 55.3 1557.0 48.9 51.1
±4.3 ±123.2 ±2.2 ±70.5 ±0.2 ±0.2
184.0 6164.7 79.3 2657.2 43.1 56.9
104.2 3428.1 73.4 2414.2 70.4 29.6
132.3 4259.4 63.6 2047.8 48.1 51.9
158.5 4516.4 68.0 1938.4 42.9 57.1
144.8 4592.2 71.1 2264.4 51.1 48.9
±17.1 ±573.3 ±3.4 ±165.8 ±6.5 ±6.5
n.s. n.s. p < 0.01 p < 0.01 n.s. n.s.
CHAPTER V
DISCUSSION
Apolipoprotein and Lipid Composition 
of Serum Lipoprotein Fractions
Results obtained in the present study and those reported previ­
ously (12, 104, 105, 109, 153) indicate that the HDL are the principal 
lipoproteins in dog plasma. Three antigenic components, designated A%,
A2 and Ag were demonstrated consistently in purified HDL fractions. The 
A]̂ - and A^-components had similar immunoelectrophoretic behavior and dis­
tribution among the lipoprotein fractions, suggesting the possibility 
that these two reactions may reflect antigenic components of apolipopro­
tein sub-units having analogous polypeptide structures. The immunoelec­
trophoretic behavior and distribution among the lipoprotein fractions 
served to differentiate HDL containing the Aj-component from those in 
which the A^- and A^-components were found. These observations support 
the conclusion that at least two groups of lipoproteins, which differ in 
their immunologic characteristics and hydrated densities are present in 
HDL of canine plasma. Furthermore, in HDL the proportion of the Ag-re- 
acting component, relative to the A^- and A^-components, appears to in­
crease with increasing hydrated density and decreasing particle size 
(later elution in gel filtration). Composition analysis of the purified, 
lipoproteins in HDL subfractions indicates that the ratio of phospholipid
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to protein decreases as the density of the subtraction increases. Al­
though these observations may reflect differences in the lipid binding 
properties of the apolipoproteins present in these two groups of lipo­
proteins, additional studies of HDL subtractions will be required to 
evaluate the relationship between the quantitative distribution of these 
antigenic components and lipids in the spectrum of HDL.
The electrophoretic mobility of canine HDL and the water solu­
bility of the apolipoprotein preparation obtained after total delipidiza- 
tion of this fraction are similar to characteristics described for human 
HDL (25). Scanu and Page (205) and Furman and co-workers (52) reported 
studies in the dog and man, respectively, in which HDL apolipoprotein 
labeled with was injected and found to be metabolized at a similar
rate to native HDL containing labeled apolipoprotein. This observation 
suggests that HDL apolipoprotein is not significantly altered by removal 
of lipids. This conclusion is further supported by results obtained in 
the present study in the dog, as well as by Scanu and co-workers (206) 
in man, demonstrating that delipidization produced no change in the im­
munochemical characteristics of HDL apolipoprotein. Rodbell and Fred­
rickson (18) reported that the N-terminal amino acids of delipidized ca­
nine serum HDL and LDL were similar to those of human serum, i.e., aspar­
tic acid in HDL and glutamic acid in LDL. However, the polypeptide fin­
gerprint patterns of hydrolysates of canine HDL protein were different 
from those obtained with human HDL protein. In the present study differ­
ences in immunochemical characteristics and amino acid composition were 
detected between canine and human apolipoprotein A. The present results 
of the amino acid analysis of purified HDL of d 1.110-1.250 g/ml are gen-
107
erally similar to those reported for dog serum HDL by Wathen and Levy 
(207) . Minor discrepancies between these results may be due to differ­
ences in the methods of isolation, purification and analysis, as well 
as in the segment of HDL utilized for study. Canine HDL apolipoprotein 
contains less histidine, lysine, methionine, phenylalanine, threonine 
and tyrosine than human (208). Nevertheless, the appearance of the im­
munoelectrophoretic and disc electrophoretic patterns of apolipoprotein 
A as well as the quantitative chemical composition of HDL from canine 
serum are similar to those reported for human samples (23, 38, 209-211). 
Thus, the present study suggests that apolipoprotein A in the dog resem­
bles that in man in respect to its heterogeneity and complexity, but dif­
fers in specific components and/or chemical composition.
The nature of the plasma component which exhibited the A%-reac- 
tion when reacted with anti-HDL or anti-VLDL serum is only partially dis­
cernible from the present study. This antigenic component was demonstra­
ted consistently, but in very small quantities, in purified VLDL and in 
serum samples from which lipoproteins of d < 1.250 g/ml had been removed. 
In addition, the Ax-reaction was observed in unpurified, but not purified, 
HDL preparations, although antibodies which produced this reaction were 
elicited in rabbits following the administration of some purified HDL 
preparations. These observations suggest the possibility that the pro­
tein or other component responsible for this reaction is highly antigenic. 
Evidence presented herein that the Ax-component disappears from the HDL 
fraction during purification and is recovered in the infranatant portion 
during the washing procedure may indicate that this component is inter­
acting with HDL in a relatively reversible manner, possibly by simple ad­
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sorption to the lipoproteins. A similar explanation may account for the 
presence of the A%-component in the VLDL fraction. Lewis and Page (212) 
have described complexes containing immunoglobulin and lipoproteins in 
subjects with lipemia. A second possibility is that the A%-component re­
flects a specific antibody to lipoproteins similar to the auto-antibodies 
described in human subjects by Beaumont and Lorenzelli (213). Evidence 
favoring this conclusion is provided by the immunoelectrophoretic behav­
ior of the Ax-component, i.e., its migration to the y-globulin region, 
and the demonstration that antibodies to this component are present in 
anti-canine y-globulin serum. Additional evidence favoring the conclusion 
that the Ax-component is a y-globulin is provided by the elution of this 
component in the fractions containing y-globulins when whole serum or li- 
poprotein-free serum was subjected to Sephadex gel filtration. A third 
possibility is that the Ax-component represents a distinct apolipoprotein, 
i.e., this component is capable of binding lipids. Additional assessment 
of these alternatives and of the significance of the Ax-component in re­
spect to canine plasma lipoproteins must await further investigation.
Purified LDL contained primarily apolipoprotein B, although var­
iable amounts of lipoproteins containing A- and X-components were found 
in several preparations. This finding is similar to that reported by Lee 
and Alaupovic (35) for human LDL fractions. Analysis of this lipoprotein 
fraction indicated a high ratio of phospholipid to protein, due primarily 
to relatively less protein and greater proportions of cholesterol and tri­
glyceride than were found in the HDL fractions. Antigenic similarity (B- 
reaction) between canine and human LDL was observed in the present study 
and by Storiko and Fisher (113).
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Immunochemical analysis demonstrated that purified VLDL contained 
two components, i.e., and B, which were also found in higher density 
fractions. In addition, a third component designated X was observed con­
sistently in this fraction. Results from these immunochemical analyses 
suggest that the VLDL fraction contains a group of lipoproteins in which 
the apolipoprotein is unique. A similar thesis concerning VLDL in human 
plasma has been advocated by Gustafson and co-workers (21, 22), who first 
recognized the presence of lipoproteins containing a unique apolipoprotein 
and proposed its designation as apolipoprotein C. The possibility exists 
that the X-component in canine VLDL corresponds to the apolipoprotein C 
found in man. The immunoreaction between anti-canine VLDL serum and human 
chyle VLDL is identical with the C-reaction observed when anti-human VLDL 
serum and human chyle VLDL are reacted. Electrophoretic analysis of par­
tially delipidized "lipoproteins from canine serum in 7% polyacrylamide gel 
demonstrated protein bands which are similar to those found by McConathy 
and Alaupovic (32) in partially delipidized VLDL from human chyle. More­
over, the distribution in canine serum of lipoproteins containing the X- 
component is similar to that in human plasma of lipoproteins containing 
apolipoprotein C (32, 35).
VLDL contained primarily triglycerides, with relatively small 
proportions of phospholipids and cholesterol. However, the protein con­
tent of serum VLDL was higher in dogs than has been observed in man (46, 
214, 215). Yokoyama and Zilversmit (216) found that dog lymph chylomi­
crons less than 140 mp in diameter contained almost 10% protein, whereas 
the protein content of larger chylomicrons was less. Few, if any, large 
chylomicrons may have been present in the fraction of d < 1.006 g/ml iso­
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lated in the present study, inasmuch as the serum samples for composition 
analysis were obtained from dogs which were being maintained on a low-fat 
diet and had been fasted for at least 20 hr.
Results described herein provide evidence that the HDL, LDL and 
VLDL fractions in canine plasma have relatively distinct immunologic char­
acteristics. Nevertheless, the frequency with which lipoproteins contain­
ing an apolipoprotein characteristic of one density range were found in 
purified fractions isolated at an adjacent density, e.g. the demonstra­
tion of the apolipoprotein containing the A-component in the LDL fraction 
and the apolipoprotein containing the B-component in the lower density HDL 
sub-fractions, indicates that in the dog, as in man (23, 217), the use of 
conventional density boundaries for classifying lipoproteins has limited 
applicability. A classification system based on apolipoproteins, as advo­
cated by Alaupovic (23, 38) for human serum lipoproteins, is favored by 
the present findings in the dog.
Lewis and co-workers (12) have observed that "the lipoprotein 
concentration, determined at density 1.063, of healthy mongrel dog sera 
varied greatly from animal to animal". Therefore, these authors suggested 
that "changes must be evaluated by using the animal's own pattern as con­
trol". In the present study substantial individual variations were found 
not only in serum lipid levels and lipid distribution, but also in the 
apolipoprotein composition of lipoprotein fractions, particularly those of 
d < 1.110 g/ml. This variability may well be the underlying reason for 
the conclusions presented by these investigators.
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Effect of Methyltestosterone on the Apolipoprotein and Lipid 
Composition of Serum Lipoprotein Fractions 
and on Serum Proteins
The reduction in serum lipids observed in the present as well as 
previous studies (153, 155) in dogs given methyltestosterone is associated 
with an equivalent reduction in apolipoprotein concentration. Changes in 
the distribution of apolipoproteins and lipids among the lipoprotein frac­
tions, as well as alterations in the composition of individual lipoprotein 
fractions, were also observed. Methyltestosterone diminished the propor­
tion of total serum apolipoproteins, cholesterol and phospholipid and in­
creased the proportion of triglyceride present in lower density lipopro­
teins, i.e., those of d < 1.063 g/ml. Methyltestosterone also increased 
the triglyceride content in all fractions except the HDL fraction of d 
1.110-1.250 g/ml and increased the ratio of phospholipid to protein in all 
fractions except that of d < 1.019 g/ml. This increase in phospholipid 
relative to protein is consistent with a decrease in lipoproteins contain­
ing HDL apolipoproteins, inasmuch as the latter lipoproteins have a much 
lower phospholipidiprotein value than lipoproteins containing apolipopro­
teins B and X. Immunochemical analysis of the apolipoprotein changes pro­
duced by methyltestosterone demonstrated a marked diminution of apolipo­
protein A in the lower density fractions, without a comparable decrease 
in apolipoproteins containing the B- and X-components. These observations 
suggest that methyltestosterone may produce a re-distribution of trigly­
ceride and other serum lipids primarily through a selective effect on HDL 
apolipoproteins. A significant diminution of apolipoprotein A might re­
sult in a greater proportion of plasma triglyceride being transported in 
triglyceride-rich, lower density lipoproteins, especially in the dog in
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which this apolipoprotein may comprise as much as 90% of total apolipo­
proteins. Further evidence supporting the conclusion that methyltestos­
terone reduced the concentration of apolipoprotein A was obtained from 
immunochemical and quantitative chemical analyses of the HDL fractions. 
Although no qualitative changes were demonstrated by immunochemical 
analyses, marked diminution in the quantity of all HDL components was 
observed. The amino acid composition of apolipoprotein A was not altered 
appreciably by methyltestosterone, providing further support for the con­
clusion that methyltestosterone produces a quantitative, rather than a 
qualitative change in the HDL apolipoproteins.
Methyltestosterone produced a significant reduction in all den­
sity classes of lipoproteins. This observation might be interpreted as 
indicating that HDL and LDL apolipoproteins, as well as other components, 
were affected similarly by methyltestosterone. Additional results obtain­
ed in this study, however, fail to support this conclusion. The diminu­
tion in LDL comprised a proportionately greater reduction in lipoproteins 
containing apolipoprotein A than in those containing apolipoproteins B or 
X. These results indicate that methyltestosterone alters primarily lipo­
proteins containing apolipoprotein A. Moreover, these observations empha­
size that criteria in addition to hydrated densities and conventional lip­
id analyses are necessary to permit meaningful evaluation of the response 
to agents which alter lipoprotein metabolism.
Methyltestosterone produced a statistically significant increment 
in albumin concentration and decrement in ai~ and 3-globulins, without al­
tering total protein levels in serum. Although ag-globulin concentration 
was not changed in the present study, an increase has been observed in
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other studies in our laboratory. Little information is available concern­
ing the effect of methyltestosterone on albumin and other serum protein 
fractions. In patients given testosterone, no changes were observed in 
serum total protein concentration (140). Norethandrolone administration 
to human subjects increased the concentration of the pre-albumin fraction 
which binds thyroxine (143). In addition, it has been suggested that this 
agent (143) or methyltestosterone (142) diminished the concentration of 
the «i-globulin which binds thyroxine. Natural androgens and synthetic 
anabolic steroids have been found to increase the ag-globulin concentra­
tion (144). These observations suggest that the serum protein response 
in dogs given methyltestosterone resembles changes observed in human sub­
jects given this or related agents. Nevertheless, clinical investigations 
in which a number of anabolic steroids were used demonstrated no consis­
tent effects on serum total protein concentration or individual protein 
fractions (218). Attempts to relate structure of these agents to their 
pharmacological activity have generally proved unsuccessful.
Effect of Me thy1tes tos terone on the Incorporation of ^^C-Lysine 
into the Apolipoproteins of Serum HDL and LDL and 
Serum Albumin and on the Turnover of 
HDL Apolipoprotein and Albumin
The metabolic steady state established by prolonged administra­
tion of methyltestosterone was characterized by a significant decrease in 
the concentration of apolipoprotein A and an increase in albumin concen­
tration in serum. The incorporation and turnover studies provide inform­
ation concerning the metabolic status of these proteins during methyl­
testosterone treatment. Results from these studies may permit inferences 
concerning the possibility that changes in the rates of apolipoprotein
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synthesis or degradation may represent the primary metabolic response to 
methyltestosterone.
In the metabolic steady state, the rate of synthesis of a metab­
olite equals the rate of degradation. A new steady state, e.g. that char­
acterized by diminished concentration of a protein, can be produced by any
of the following;
1. an increase in the space of distribution,
2. an increase in the rate of degradation, and
3. a decrease in the rate of synthesis.
If methyltestosterone were to alter only one of these variables, the rela­
tionship between the total exchangeable pool and the half time of apolipo­
protein A in response to the changes listed above would be as follows:
1. Pool(c) = Pool(Ml); T/2(c) =
2. Pool(c) > Pool(MT); T/2(qj > T/2(^Y)
3. Pool(c) >Poo1(mt); T/2(c) = T/2(̂ .p)
Inverse relationships to those listed above would characterize a new 
steady state in which the pool size was increased, i.e., that observed 
with albumin during methyltestosterone administration.
The observation that methyltestosterone reduced the pool size
but not the half time of apolipoprotein A favors the conclusion that a
decreased synthesis rather than an accelerated degradation was respons­
ible for the diminished apolipoprotein A concentration in plasma. Simi­
larly, since the half time of albumin was less while the albumin pool was 
enlarged significantly, it appears that methyltestosterone stimulated the 
synthesis of albumin rather than inhibiting the catabolism of this pro­
tein. Thus, results obtained in the turnover studies are consistent with
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the amino acid incorporation studies and indicate that apolipoprotein A 
synthesis is decreased and albumin synthesis increased by methyltestos­
terone .
The time course of the incorporation of labeled lysine into 
apolipoprotein A and albumin was similar before and during methyltestos­
terone treatment. Approximately 50% of the maximum radioactivity incor­
porated into each protein was reached within 1 hr. However, there was a 
significant difference in the amount of radioactivity incorporated into 
apolipoprotein A and albumin before and during methyltestosterone treat­
ment, suggesting an opposite change in the rate of synthesis of these 
two proteins. This is reflected in the significant decrease in the HDL: 
albumin protein radioactivity ratios during methyltestosterone treatment, 
as compared with the control state.
Calculations based on the fractional turnover times of these
proteins indicate that less than 5% of circulating protein is degraded
14during the first few hours after C-lysine injection. Therefore, any 
effect of catabolism on the specific radioactivities measured in the in­
corporation study must be negligible. Apolipoprotein A and albumin may 
not equilibrate at an equal rate with the extravascular pool during the 
12-hr period of this study. Results obtained from the turnover studies 
suggest that albumin may equilibrate more rapidly than apolipoprotein A. 
If this conclusion were correct, the values presented for HDL:albumin 
radioactivity ratios would be higher than true values, and the effect of 
methyltestosterone on this ratio underestimated. The presumption that 
these proteins are synthesized from the same amino acid pool in liver 
eliminates any problem concerning the effect of possible differences in
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the intracellular pool size of precursor before and during treatment.
Studies by Wilcox and co-workers (89) of the incorporation of 
labeled lysine into serum apolipoproteins in the isolated perfused rat 
liver and by Fried and co-workers (219) in five species of higher animals 
other than the dog suggest that LDL apolipoproteins are synthesized and 
degraded more rapidly than are those in HDL. Results obtained in the 
present study indicate that specific radioactivities differ significantly 
among the three proteins. Highest values were observed in LDL and lowest 
in albumin. Results from incorporation studies in the pig, rabbit and 
chicken are similar to those we obtained in the dog, in so far as HDL 
apolipoprotein and albumin are concerned. However, the rapid decline in 
LDL radioactivity which has been found in other animals was not observed 
in the dog. The presence in canine LDL of apolipoprotein A, which appar­
ently has a longer turnover time than apolipoprotein B, may be a factor 
in the slower LDL turnover in this species. This possibility is supported 
by the observation that a proportionately greater incorporation into LDL 
apolipoproteins occurred in those dogs, especially Dog 104, in which apo­
lipoprotein A represented a greater portion of the protein moiety than in 
others. Methyltestosterone treatment appears to eliminate these differ­
ences by reducing apolipoprotein A in LDL. During methyltestosterone 
treatment the specific radioactivity of albumin was unchanged or lower 
and that of the apolipoproteins higher than in the control state, due to 
changes in the pool sizes.
Little information is available concerning the regulation of apo­
lipoprotein synthesis, although the importance of unimpaired protein syn­
thesis for normal lipid transport is well established (64, 65, 89, 98, 99,
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220). The effect of several hormones on synthesis of LDL apolipoprotein 
has been studied in the rooster by Florsheim and co-workers (221), using 
labeled methionine and tyrosine. Results reported by these investigators 
demonstrated that the time course of incorporation, as well as the rela­
tive amounts of radioactivity incorporated into LDL apolipoprotein, al­
bumin and 'other proteins', were similar to those obtained in the present 
study. Estrogens produced a marked increase in LDL apolipoprotein and 
cholesterol concentrations in plasma and also increased more than ten-fold 
the total radioactivity incorporated into the apolipoprotein. L-triiodo- 
thyronine depressed somewhat the lipoprotein levels but produced a marked 
increase in apolipoprotein specific radioactivity. Cortisone had little 
effect on either lipoprotein levels or specific radioactivity of LDL apo­
lipoprotein. Interpretation of these results is complicated by the fail­
ure of these investigators to evaluate the possibility that hormone- 
"nduced changes in intravascular:extravascular distribution, which have 
been observed (222, 223) may be a factor in their study. Nevertheless, 
the magnitude of increase in incorporation during estrogen treatment 
leaves little question that apolipoprotein synthesis is increased. This 
response is the converse of that obtained in the present study with meth­
yltestosterone.
Methyltestosterone produced an increase in albumin synthesis and 
a decrease in apolipoprotein synthesis. The possibility might be consid­
ered that a reciprocal relationship exists in the metabolism of these 
proteins, i.e., that an acceleration in the rate of albumin synthesis in 
liver is associated with a reciprocal attenuation of the rate of apolipo­
protein synthesis and vice versa. In nephrosis, hypoalbuminemia is asso-
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dated with hyperlipoproteinemia, representing the converse state to that 
produced by methyltestosterone. Hepatic synthesis of LDL (224) and HDL 
(86) apolipoproteins is accelerated in this disorder and probably accounts 
for the hyperlipoproteinemia. Moreover, albumin synthesis is also en­
hanced (225-228), but the rate of synthesis is inadequate to replace the 
large quantities of albumin which are lost through the defective glomeru­
li. The response to dextran is another instance in which apolipoprotein 
and albumin synthesis are not related reciprocally. Dextran produces hy­
poalbuminemia without lipemia. This response is associated with a de­
crease in albumin synthesis (229) . Furthermore, in experimental nephro­
sis (230) and in cortisone-induced lipemia (231), dextran has a lipid 
lowering effect which apparently reflects a re-distribution of lipopro­
teins to the extravascular pool, rather than any change in apolipoprotein 
synthesis (232). These observations suggest that the rate of albumin syn­
thesis is not necessarily related to the plasma concentration of albumin 
and that apolipoprotein and albumin synthesis are not reciprocally re­
lated.
The possible role of an androgen-induced fat mobilization (168) 
in respect to the changes in albumin synthesis produced by methyltestos­
terone should be considered, inasmuch as increased free fatty acid influx 
into the liver could increase synthesis of albumin for transporting free 
fatty acids in plasma. If free fatty acid influx into the liver were in­
creased, an accelerated hepatic synthesis of triglycerides should be evi­
dent through increased serum triglyceride levels (233). Furthermore, 
changes in free fatty acid influx were found by Ruderman and co-workers 
(102) to alter the synthesis of VLDL apolipoproteins without influencing
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other apolipoproteins or other serum proteins.
Methyltestosterone might also influence lipoprotein metabolism 
through androgen-like effects on thyroid function. Administration of 
methyltestosterone or norethandrolone to human subjects produced a fall 
in thyroxine-binding capacity of the thyroxine-binding globulin and in­
creased the fractional turnover rate of thyroxine (142, 143). On the 
other hand, the association of serum lipid abnormalities with thyroid 
dysfunction is well recognized. In hypothyroid subjects, LDL are in­
creased while in thyrotoxicosis LDL and HDL are decreased (234-237).
These changes probably reflect more generalized alterations in protein 
metabolism, since the metabolism of LDL apolipoprotein (238), albumin 
(239) and yglobulin (240) were affected in a similar manner by altera­
tion in thyroid activity. Hence, it appears unlikely that methyltestos­
terone is mediated through the thyroid.
Half time values for the apolipoprotein of canine serum HDL (d
1.063-1.210 g/ml) of approximately 3.5 days have been reported by Scanu 
and Page (78, 205). Similar values were obtained for intact lipoprotein 
or the lipid-free protein moiety both in the dog (205) and in man (52,
59). These values compare favorably with those obtained in the present 
study. However, no data are available concerning the time sequence of 
the distribution of apolipoprotein radioactivity among various lipopro­
tein classes. Results from the present study suggest a continuous trans­
fer at a relatively constant rate from high density (d 1.110-1.250 g/ml) 
to lower density (d < 1.110 g/ml) lipoprotein fraction. Individual trans­
fer rates were of similar magnitude to the amount of apolipoprotein A in 
fraction of d < 1.110 g/ml, i.e.. Dog 104; > Dog 181 > Dogs 233 and- 236.
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These individual variations were apparently reflected also in the half 
times obtained for disappearance of radioactivity from serum, inasmuch 
as the turnover of apolipoprotein A within the fraction of d 1.110-1.250 
g/ml was practically the same in each dog. Furthermore, the significant 
reduction of apolipoprotein A in the lower density fractions during meth­
yltestosterone administration was accompanied by a barely detectable 
transfer of radioactivity into this fraction and by shorter overall half 
time values in those dogs in which the greatest transfer was observed in 
the control state, i.e.. Dogs 104 and 181. Although these observations 
suggest that a transfer of apolipoprotein A from high to lower density 
lipoproteins occurs, they do not favor the conclusion that an exchange 
takes place among different apolipoproteins, i.e., apolipoprotein A does 
not exchange with apolipoprotein B. A similar conclusion has been advo­
cated by Scanu and Page (205). The lower turnover rates for apolipopro­
tein A in serum, when compared with those in HDL (d 1.110-1.250 g/ml), 
suggest the rate of removal of apolipoprotein A is much slower in 
lower density lipoproteins. The possibility exists that the transfer of 
radioactivity observed here represents only a continuous equilibration of 
apolipoprotein A within the lipoprotein spectrum, or alternatively that 
this represents a metabolic sequence through which at least part of the 
apolipoprotein A from HDL normally passes before being removed from the 
circulation. Additional studies will be required to evaluate these and 
other possible explanations for these observations.
Methyltestosterone produced a much greater reduction in the total 
exchangeable pool for apolipoprotein A in HDL (d 1.110-1.250 g/ml) and 
serum than in the half time for this protein. The reduction in the ex­
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changeable pool of apolipoprotein A was much greater than predicted from 
changes in the intravascular pool alone, due to a significant shift of 
apolipoprotein A from the extravascular to the intravascular compartment.
Individual components of lipoproteins have been shown to turn 
over with significantly different rates. Scanu and Page (78) obtained 
the following half time values in canine serum: cholesterol, approxi­
mately 8 days; phospholipids, 36 hr; triglycerides, 10 min; LDL apo­
lipoprotein (d 1.006-1.063 g/ml), 2.3 days; and HDL apolipoprotein (d
1.063-1.210 g/ml), 3.5 days. The observation that serum lipid levels de­
creased to a similar extent as the apolipoprotein concentrations suggests 
that their metabolism may have been altered similarly by methyltestoster­
one, possibly through the decreased availability of the transport pro­
tein.
The intravascular and extravascular spaces for albumin were in­
creased to an equivalent extent during methyltestosterone treatment. Con­
sequently, the increase in the total exchangeable pool of albumin was much 
greater than appeared from the serum concentration. Inasmuch as the half 
time also decreased, these results indicate that the production rate for 
albumin was much greater during methyltestosterone treatment than in the 
control state. Methyltestosterone thus appears to produce an increased 
rate of albumin synthesis, i.e., the accumulation of albumin is not due 
to a decreased rate of degradation. The decreased half time during meth­
yltestosterone treatment is possibly due to a metabolic adjustment to the 
increased rate of synthesis caused by methyltestosterone. Control values 
for the half time and turnover rate of albumin obtained in this study are 
similar to those observed in humans (241).
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The increase in intravascular space demonstrated in response to 
methyltestosterone using either protein is in agreement with previous ob­
servations (142) and it is possibly due to the fact that androgens cause 
positive balances of nitrogen, phosphorus and water (242). It seems like­
ly, however, that the increased albumin production and albumin pool de­
scribed here could also be a factor in increasing these spaces.
The extrapolation method of Sterling (202) used in this study 
for estimating total pool size and turnover rate was applied initially 
to studies of the metabolism of ^^^I-labeled human serum albumin. A num­
ber of other analytical methods have been advocated for protein turnover 
studies (243). The Sterling method is an "approximation method", rather 
than one in which "specific models" are based on multi-exponential analy­
sis of plasma curves (244). It has been stated that the Sterling method 
tends to over-estimate the total pool and the turnover rate, due to the 
fact that the final slope of the plasma curve is altered by the presence 
at this time of a higher specific radioactivity in the extravascular pool 
than in the intravascular pool. Nevertheless, results obtained by this 
method have provided acceptable values in studies with human albumin in 
normal subjects when different methods of analysis were compared (241). 
Furthermore, the basic assumption of the Sterling procedure, i.e., that 
uniform specific radioactivity is attained throughout the intravascular 
and extravascular compartments after an equilibration period, was support­
ed by direct determination of extravascular albumin in the rat. In this 
latter study Sellers and co-workers (245) also showed that among the dif­
ferent methods of analysis the extrapolation method of Sterling gave the 
closest values to those obtained with direct quantitative immunochemical
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determinations of the extravascular albumin pool.
The general assumption made in plasma protein turnover studies 
is that the newly synthesized protein enters the intravascular compart­
ment before mixing with the extravascular compartment. This assumption 
has been recently substantiated by the findings of Smallwood and co­
workers (246) in the dog for albumin and fibrinogen synthesized in the 
liver. In the present study the observation that the HDL;albumin radio­
activity ratios were higher at 0.5 hr after precursor injection than at 
later intervals suggests that the newly synthesized apolipoprotein A is 
released into the circulation more rapidly than albumin. Therefore, apo­
lipoprotein A must enter the intravascular compartment directly.
The cholestatic properties of C^y-alkylated steroids in human 
subjects are well known. The possibility that the changes in protein and 
lipid metabolism described herein are secondary to methyltestosterone- 
induced hepatotoxicity seems most unlikely, however, inasmuch as consider­
able evidence is available which indicates that the canine liver lacks the 
sensitivity to this agent which characterizes the response in man. The 
relative insensitivity in the canine response may be due to a more rapid 
excretion of methyltestosterone in the dog, when compared with man (159, 
183). A similar accelerated excretion has been observed with testoster­
one (186). Tests of liver function were normal in the present and previ­
ous (153, 156) studies in this laboratory. In addition, electron micro­
scopic and other morphological evaluations demonstrated no clear-cut 
changes in liver from dogs treated with methyltestosterone.
Results obtained in the present study indicate that methyltestos­
terone produces opposite effects on the synthesis of two proteins formed
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in the liver. The possibility exists that this agent may prove useful in 
studies of the regulation of apolipoprotein and other protein synthesis 
in the liver.
It can be concluded that methyltestosterone significantly reduces 
the production of the principal apolipoprotein in canine serum lipopro­
teins . This should result in diminished production in the cell and/or 
transport from the cell of lipid components of the lipoproteins (76). In 
fact, decreased cholesterol synthesis during methyltestosterone treatment 
was observed by Furman and co-workers (156) following ^^C-acetate incor­
poration in the dog. This observed decrease in serum cholesterol forma­
tion, however, does not explain the concomitant methyltestosterone-induced 
decrease in phospholipids and triglycerides in serum. On the other hand, 
an impairment of apolipoprotein synthesis, such as demonstrated in the 




1. Lipoprotein fractions were isolated from canine serum by 
sequential preparative ultracentrifugation and purified. Immunochemical 
and quantitative chemical analyses were performed to characterize their 
apolipoprotein and lipid composition.
2. High density (d 1.063-1.210 g/ml) and very high density (d
1.210-1.250 g/ml) lipoproteins contain most of the cholesterol and phos­
pholipid present in canine serum and at least two immunologically dis­
tinct apolipoprotein components (A1-A2 and A3). Relatively more protein 
and phospholipid are present in these fractions than in lower density li­
poproteins and the amounts of cholesterol and triglyceride are relatively 
less. As the hydrated density of high density lipoprotein subfractions 
increased; the ratio of phospholipid to protein decreased and proportion­
ately greater amounts of the lipoprotein characterized by the Ag-antigenic 
component, relative to A^ and A2, were found. Differences in immunochemi­
cal characteristics and amino acid composition suggest that the apolipo­
protein A of canine serum is distinct in specific components and/or chemi­
cal composition from the human.
3. Low density lipoproteins (d 1.006-1.063 g/ml) contain prima­
rily apolipoprotein B which is also demonstrable in very low density lipo­
proteins (d < 1.006 g/ml). In addition, the very low density lipoprotein
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fraction contains apolipoprotein X, which may correspond with the apolipo­
protein C found in human plasma.
4. Immunochemical analyses also demonstrated the presence of
very small quantities of an unusual protein component in purified very
low density lipoproteins, in unpurified but not in purified high density 
lipoproteins and in the serum sample from which lipoproteins of d < 1.250 
g/ml had been removed. This component migrated on immunoelectrophoresis 
as a y-globulin and also reacted with anti-canine y-globulin serum. These 
observations suggest the possibility that this protein is a specific auto­
antibody to canine lipoproteins, although alternative explanations are 
possible.
5. Lipoproteins containing an antigenic component characteris­
tic of one density range were often found in purified, i.e., albumin-free 
lipoproteins isolated in an adjacent density range, supporting the conclu­
sion that in the dog, as in man, a lipoprotein classification system based
solely on hydrated densities has limited applicability.
6. Methyltestosterone reduced the apolipoprotein, cholesterol, 
phospholipid and triglyceride concentration in each fraction. Less of the 
total apolipoprotein, cholesterol and phospholipid and a greater propor­
tion of the triglyceride in serum lipoproteins was found in the fraction 
of d < 1.063 g/ml during methyltestosterone administration. Methyltestos­
terone diminished the protein content of all lipoprotein fractions and in­
creased the phospholipid to protein ratio in each fraction except that of 
d < 1.019 g/ml.
7. Immunochemical analyses demonstrated that methyltestosterone 
markedly reduced the intensity of the A-reactions, i.e., the antigenic
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components characteristic of the principal apolipoproteins in high den­
sity lipoproteins. These apolipoproteins are also found in purified low 
density lipoprotein fractions isolated from control serum, but are mark­
edly diminished during methyltestosterone treatment. Methyltestosterone 
produced no change in the amino acid composition and immunochemical char­
acteristics of apolipoprotein A. Evidence is presented which favors the 
conclusion that methyltestosterone selectively reduces the concentration 
of apolipoproteins which contain the A-antigenic components.
8. Methyltestosterone increased albumin concentration and de­
creased ai- and 8-globulins significantly, without altering total protein 
concentration in plasma. No evidence of hepatotoxicity was observed in 
response to methyltestosterone.
9. Incorporation of ^'^C-lysine into the protein moiety of high 
density lipoproteins (d 1.110-1.250 g/ml) and albumin was studied in meta­
bolic steady states before and during methyltestosterone administration. 
The proportion of radioactivity incorporated into apolipoprotein A was 
significantly decreased while that incorporated into albumin was in­
creased, suggesting a selective and opposite change in the rate of syn­
thesis of these proteins in response to methyltestosterone.
10. High density lipoproteins (d 1.110-1.250 g/ml) containing 
^^C-apolipoprotein A and ^^C-albumin were obtained from a donor dog given 
l^c-lysine and used to evaluate the turnover rate and half time of these 
proteins before and during methyltestosterone administration. Methyltes­
tosterone markedly decreased the total exchangeable pool and turnover rate 
of apolipoprotein A without significantly altering half time. The albumin 
pool and turnover rate increased significantly and half time decreased.
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11. Results obtained in the incorporation and turnover studies 
indicate that methyltestosterone significantly and conversely affects the 
production of two proteins synthesized in the liver, i.e., apolipoprotein 
A synthesis decreases and albumin synthesis increases. These results are 
consistent with the conclusion that methyltestosterone exerts a primary 
effect on the synthesis, rather than on the degradation, of these pro­
teins. Reduction in the synthesis of apolipoprotein A, which may comprise 
as much as 90% of total apolipoproteins in canine serum, may explain the 
diminished concentrations in all serum lipids and lipoprotein fractions 
produced by methyltestosterone.
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